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 The use of small molecule modulators of protein function (drugs) has 
gained in popularity due to the speed and precision with which they can work.   
Unfortunately, a small molecule with the required specificity and potency is not 
always available.  We have developed two methods to generate small molecule 
sensitive protein alleles without the need to screen for a new drug. In the first, 
which we term conditional protein splicing (CPS), an intein is split into two 
inactive fragments which are activated by heterodimerization.  By fragmenting the 
target protein and fusing the pieces to this split intein, we were able to control the 
target protein’s activity through splicing.  In the second, which we term Split 
Ubiquitin for the Rescue of protein Function (SURF), a protein is expressed with 
a destabilizing N-terminal sequence (degron) that leads to its degradation.  The 
degron is removed through heterodimerization induced ubiquitin 
complementation and cleavage.   This stabilizes the protein and allows a build up 
of activity.  These techniques should allow the manipulation of a variety of 
proteins for the study of biological processes.  
 The bacterial RNA polymerase σ factors are required for promoter specific 
transcription initiation.  The σ factors responsible for driving most gene 
expression during log phase growth, known as the group 1 σ family are 
autoregulated by a poorly understood mechanism. Group 1 σ factors are unable 
to bind to DNA in the absence of core RNA polymerase.  The N-terminal domain 
of group 1 σ factors, known as region 1.1 is responsible for the auto-inhibition of 
DNA binding capabilities.  However, since in all crystal structures of bacterial 
RNA polymerase, region 1.1 is either absent or not resolved, it is not clear how 
region 1.1 works.  We used NMR to determine the structure of region 1.1 and 
intramolecular crosslinking to provide evidence that region 1.1 acts by directly 
binding to the DNA binding domains of group 1 σ factors. 
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Chapter 1 : Introduction 
 
Section 1.1 : Overview 
 
 Small molecule agonists or antagonists of protein function (drugs) have a 
number of attractive features for the study of biological processes [1].  The most 
prominent is the speed by which they work.  Upon binding, small molecules can 
effect an almost immediate knock-out or knock-in of protein function.  Thus, in 
cell culture the effects are often limited only by diffusion and in animal studies, 
limited only by the rate at which the drug is distributed to the tissue type of 
interest.  This speed allows the detailed study of very rapid processes such as 
mitosis or cell signaling which are difficult to investigate using slower genetic 
methods. 
 Sometimes, it is not simply the presence or absence of a protein’s activity 
that is required for a biological response, but a specific level of activity.  Genetic 
techniques such as mutations, knock-outs or RNAi do not allow a titration of 
protein activity.  Gene copy number is not linearly correlated with protein activity 
and RNAi gives a binary response.  In contrast, by varying the drug dose, one 
can achieve anywhere from a minor perturbation to an almost complete knock-
out. 
 Finally, the effects of small molecules are reversible or at least can be 
confined to a specific time window. This can simply require waiting for the drug to 
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be metabolized or excreted.  In cell culture, one can achieve an even more rapid 
drug clearance by washing the cells with drug-free media.  In some cases, an 
antidote small molecule is available that can attenuate the drug’s effects without 
the need for a wash.  This can allow one to, for instance, isolate the effects of a 
protein during a specific day (or potentially even hour) in development. 
 The biological processes that have been studied using small molecules 
are too numerous to mention here.  The approach, whether going by the name 
chemical biology, pharmacology or simply biology has proven itself versatile and 
powerful.  However, drugs with the required specificity and potency for biological 
studies are not available for all the proteins in the cell.  If one requires the speed, 
dosing and reversibility of a small molecule inhibitor but one is not available for 
the protein in question, one is faced with a choice.  One can try to find a new 
drug, whether by design, by screen or by both or one can modify the target 
protein to be responsive to a drug that is already available.   
 The most direct way to design a protein to be sensitive to a drug is what is 
known as the “bump and hole” strategy (Figure 1-1).  Sometimes, a potent 
inhibitor is available, but it is not specific enough, most commonly when the 
protein of interest is a member of a large protein family with diverse roles such as 
the kinases.  Since the substrate binding pockets of all kinases are broadly 
similar, an inhibitor designed against one kinase will often inhibit others leading to 
off target effects that make interpretation of the results difficult.  However, by 
making mutation(s) in the binding pocket of the target kinase and compensating 
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“mutations” in the drug, one can achieve a specific knock-down of only the 
mutated kinase, even in the presence of multiple other kinases.  The Shokat 
group has used this approach to develop specific inhibition of a variety of 
modified kinases [1-4].  The bump and hole approach was first used on GTPases 
[5, 6] and has also been used on kinesins [7] and nuclear hormone receptors [8] 
among other proteins.  The bump and hole approach will be described in more 
detail in section 1.2. 
 
Figure 1-1 : The Bump and hole approach (Section 1.2).  A small 
molecule inhibitor will often have off target effects that arise from binding 
to related proteins (left).  By simultaneously mutating the target protein 
and chemically modifying the small molecule inhibitor, one can generate a 
drug specific allele (bottom right) even in the presence of similar proteins 











Figure 1-2 : Chemical Inducers of Dimerization for the control of protein 
function (Section 1.3).  Chemical Inducers of Dimerization (CIDs) can be used 
to regulate protein function in a variety of ways.  Proteins that are naturally 
regulated by dimerization, such as membrane receptors can be activated through 
forced dimerization [9-11] (Top).  Proteins with two independent domains, such 
as transcription factors can be activated by bringing the two domains together 
[12] (Bottom Left).  Other proteins can be controlled through dimerization through 
cellular localization [13-15] (Bottom Right).  Finally, some proteins can be split 





Figure 1-2 : Chemical Inducers of Dimerization for the control of 
protein function (Section 1.3). 
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 Another popular means to sensitive a protein to an already available drug 
is the use of Chemical Inducers of Dimerization (CID, Figure 1-2).  Protein 
domains that form dimers in the presence of a small molecule can be fused to the 
target protein or fragments of the target protein to gain control over its function.  
This can most easily be applied to proteins whose function is already regulated 
by its oligomeric state.  Crabtree, Schreiber and coworkers were able to regulate 
the T cell antigen receptor complex through fusion to the FKBP domain which 
dimerizes in the presence of the molecule FK1012 [9].  This approach was also 
successfully applied to the Fas death receptor [28]. 
 Other proteins can be divided into two domains that require one another 
for proper cell function.  Fusion of these domains to dimerization domains allows 
regulation of the target proteins function with the use of a CID.  A variety of drug 
sensitive transcription factors have been generated in this way by separation into 
DNA binding domain and a transcriptional regulation domain [12].   
Sometimes CIDs can be used to regulate an enzyme’s activity simply by 
controlling its localization within a cell.  For instance, Src kinase requires 
membrane localization for enzymatic activity.  Again, Crabtree, Schreiber and 
coworkers were able to regulate the activy of Src kinase by using FKBP and 
FK1012 to control the association of the enzymatic domain of Src with a 
myristoylated, membrane anchored FKBP [13]. The use of CIDs to manipulate 
gene function will be discussed in more detail in section 1.3. 
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Figure 1-3 : Small molecule control of protein stability (Section 1.4).  
A protein’s activity can be regulated by targeting it for or rescuing it from 
degradation.  A protein can be targeted for degradation by recruiting an E3 
ubiquitin ligase with an engineered chimeric molecule (Right).  
Alternatively, by fusion to an unstable FRB*, a protein can be destabilized 
and targeted to the proteasome.  Binding to rapamycin and cellular FKBP 
stabilizes the protein and allows the build up of protein activity (Left). 
 
As an alternative to directly controlling a protein’s activity with 
dimerization, some more recent techniques control a protein’s stability (and thus, 
indirectly, its activity) with CIDs as both a knock-in and a knock-out (Figure 1-3).  
The Crews and Deshaies labs have developed a technique known as 
PROteolysis TArgeting Chimeric moleculeS (PROTACS) in which E3 ubiquitin 
ligases are recruited to a target protein through the addition of molecular 
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chimeras of a peptide that binds to a ubiquitin ligase and either the protein 
target’s substrate or a molecule that binds to a fused targeting domain.  This 
results in the ubiquitination and subsequent degradation of the target protein, 
allowing a chemical knockout [29].  Crabtree and Wandless have developed a 
destabilized FRB domain (FRB*) that, when expressed as a fusion with a target 
protein results in the degradation of the target protein [30].  Binding to rapamycin 
and cellular FKBP stablilizes both the FRB* and the fused protein allowing it to 
build up and gain activity, resulting in a chemical knock-in.  This technique has 
been applied to a variety of proteins and has even been shown to work in mice 
[31]. 
A protein’s stability can also be controlled through fusion to a single 
domain rather than through controlled dimerization.  The Wandless group has 
described a destabilized FKBP* that works in much the same manner as the 
FRB* domain works.  However, by the use of an engineered FKBP ligand, the 
FKBP* can be stabilized without dimerization, resulting in a smaller, potentially 
less invasive “tag” on the affected protein [32].  Techniques that exploit protein 
stability for control of activity are discussed in section 1.4. 
Fusion with a hormone receptor ligand binding domain (HR-LBD) is 
another method by which to build small molecule sensitivity into a target protein 
as this can result in activity that is responsive to hormones.  Conditional CRE 
recombinases have been generated in this manner, allowing genetic knock-in 
and out in a tamoxifen controlled manner [33-35].  The Liu lab has developed a 
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tamoxifen controlled intein/ER fusion [36, 37].  By insertion of this conditional 
intein into a target protein, the target protein’s activity can be indirectly controlled 
through protein splicing.  HR-LBD fusions will be discussed further in section 1.5. 
 The engineering of a target protein to make it responsive to a known drug 
is known as generating a conditional protein allele since the modified protein is 
generally genetically encoded and expressed in cells or animals using standard 
genetic techniques.  The ideal conditional protein allele is one whose “active” 
form is nearly identical to the wild type protein in both structure and activity.  The 
ideal means to generate conditional protein alleles is one that is fully general in 
that it should be applicable to virtually any target protein with a minimum of 
optimization.  Unfortunately, the methods described above, while powerful, all 
either suffer from a lack of general utility or do not generate a wild type protein. 
 The bump and hole approach requires that an inhibitor can be chemically 
modified and that the binding pocket of the target enzyme is amenable to 
mutation.  Not all proteins can be controlled by dimerization, and when they can 
be, the resulting protein is present as a fusion with the dimerization domains 
rather than in its native form.  Although it appears that nearly any protein’s 
stability can be regulated by fusion to FRB* or FKBP*, once again, the rescued 
protein is a fusion protein.  PROTACS either requires that a ligand for the target 
protein be available and amenable to chimerization or that the protein be 
expressed as a fusion with a targeting domain.  Fusion with an HR-LBD does not 
always result in a conditional allele and, once again, results in a tagged protein.  
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The conditional intein described by Liu eliminates the protein tag through splicing, 
but may not be general and has not been validated in animals at this time. 
 The majority of my thesis work has been spent on developing general 
conditional protein alleles that generate wild type (or nearly wild type) proteins.  
One approach that I have taken is to modify a technique known as conditional 
protein splicing (CPS).  In CPS, a protein splicing element known as an intein is 
split into two inactive fragments which are activated by heterodimerization.  By 
fragmenting the target protein and fusing the pieces to this split intein, I was able 
to control the target protein’s activity through splicing.  This work will be 
described in Chapter 2. 
 A second approach I have worked on relies on the control of the target 
protein’s stability.  During the development of the CPS approach, I found that 3 
tandem copies of the FRB domain destabilizes a protein when present as an N-
terminal fusion.  This triple FRB can be used in a similar manner to the FRB* 
developed by Crabtree and coworkers.  As a further evolution of the approach, 
an additional fusion with split ubiquitin was made.  Varashovsky and coworkers 
have previously shown that split ubiquitin can be reconstituted by forced 
dimerization [16] resulting in C-terminal hydrolysis by a cellular ubiquitin 
hydrolase.  The cleavage of ubiquitin removes the destabilizing triple FRB from 
the target protein, simultaneously regenerating the wild type, untagged protein 
and rescuing it from degradation.  This work will be described in Chapter 3. 
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 In addition, during my thesis work, I have worked on another, unrelated 
project.  The bacterial RNA polymerase sigma factors are required for promoter 
specific transcription initiation [38].  The sigma factors responsible for driving 
most gene expression during log phase growth, known as the Group 1 σ family 
are autoregulated by a poorly understood mechanism. Group 1 σ factors are 
unable to bind to DNA in the absence of core RNA polymerase.  The N-terminal 
domain of group 1 σ factors , known as region 1.1 is responsible for the auto-
inhibition of DNA binding capabilities [39, 40].  However, since in all crystal 
structures of bacterial RNA polymerase, region 1.1 is either absent [41, 42] or not 
resolved [43], it is not clear how region 1.1 works.  I used NMR to determine the 
structure of region 1.1 and intramolecular crosslinking to provide evidence of an 
intrasteric mode of autoregulation.  This work will be described in Chapter 4. 
 In the following sections, I will review the current techniques available for 
the generation of conditional protein alleles. 
 
Section 1.2 : Bump and Hole 
 
 In 1987, Hwang and Miller described a mutation (D138N) in Elongation 
Factor Tu (EF-Tu) which reduced its affinity for GDP but allowed it to bind to 
xanthosine 5’-diphosphate [5].  EF-Tu aids in the binding of charged tRNAs to 
ribosomes during mRNA translation and binds GDP or GTP and a charged tRNA.  
In crystal structures, the D138 side chain hydrogen bonds to the 2-amino group 
of guanine.  The D138N mutation abolishes this interaction by replacing a 
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hydrogen bond acceptor with a hydrogen bond donor.  Xanthosine differs from 
guanosine in the substitution of a carboxyl group for the 2-amino group.  Thus, 
while xanthosine cannot form a hydrogen bond with D138, it can form one with 
D138N allowing binding to the mutant but not the wild type protein.  It was further 
shown that XTP could stimulate the formation of an Ef-Tu • ribosome • tRNA 
complex with the mutant protein but not with the wild type protein.  Without 
setting out to, Hwang and Miller had in essence developed one of the first allele 
specific inhibitor – target pair. 
 Building on this finding, Powers and Walter deliberately made a similar 
mutation in another GTP binding protein, E. coli FtsY with the goal of isolating the 
effects of GTP binding FtsY as opposed to GTP binding to an FtsY interacting 
partner, Ffh [6].  Neither FtsY nor Ffh displays much GTPase activity in isolation 
but when mixed together, strong GTPase activity is observed.  However, since 
both are capable of binding GTP, it was difficult to determine which, if not both of 
the two proteins is actually responsible for this activity.  To answer this question, 
Powers and Walters generated an FtsY with a homologous mutation (D441N) to 
the one described by Hwang and Miller, creating an allele specific sensitivity to 
XTP.  The FtsY(D441N) • Ffh complex exhibited GTPase activity only in the 
presence of both GTP and XTP, which was also hydrolyzed.  This suggests that 
both FtsY and Ffh are acting as GTPases in complex and that they act to 
stimulate one another’s activity. 
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 Kapoor and Mitchison used the bump and hole approach to generate 
allele specific activators and inhibitors of kinesin [7].  Kinesins are ATPase motor 
proteins that aid in the movement of cellular components and in cytoskeletal 
organization.  The addition of a bulky cyclopentyl group at the N6 position of ATP 
creates steric clash with the ATP binding pocket of kinesin.  By mutating an 
arginine in the ATP binding pocket to an alanine, Kapoor and Mitchison were 
able to relieve this steric clash which resulted in the stimulation of the mutant’s 
but not the wild type protein’s motor activity by cyclopentyl-ATP.  A non-
hydrolyzable cyclopentyl-ATP was also able to inhibit the mutant protein, but not 
the wild type protein allowing both allele specific activation and inhibition. 
 Similarly, Shi and Koh showed that functionalizing estrogen with a 
carboxylic acid greatly reduced its ability to bind to the estrogen receptor (ER), 
likely from a combination of sterics and electrostatic repulsion.  However, a 
compensatory EA mutation in the ER LBD allowed binding to and stimulation 
by the modified estrogen [8].  The modified receptor/ligand pair could be used to 
drive gene expression without the concern of binding to native ER LBD. 
 The Shokat group has taken full advantage of the power of the bump and 
hole approach to study kinases.  Highly specific agonists or antagonists of 
protein kinases are rare due to their structural similarity, especially in the ATP 
binding pocket.  However, by adding a bulky subsituent to ATP and making a 
compensatory mutation in the target kinase, Shokat and colleagues have 
generated a variety of allele specific activators or, by making non-hydrolyzable 
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analogues, inhibitors [1].  These target/inhibitor pairs have proven to be powerful 
tools for the study of the roles and activities of kinases.  In one report, a bump 
and hole CaMKII/ATP analogue pair was used in transgenic mice to study its role 
in memory formation [4].  Through selective inhibition of the sensitized trans-
gene, it was determined that the activity level of CaMKII is crucial for the 
formation of long term memory only in the first week after “learning.” 
 In another study, the Shokat group used the Bump and Hole approach to 
identify the subtrates of the cyclin-dependent kinase Cdk1 [3].  Determining 
which proteins were phosphorylated by a specific kinase is normally impossible 
in a cell lysate.  However, by using a Cdk1 allele that was sensitized to be able to 
utilize N6-(benzyl) ATP, Shokat and co-workers were able to isolate the effects of 
a single kinase in an entire cell lysate.  Radiolabelled N6-(benzyl) ATP was added 
to a cellular extract along with the sensitized Cdk1.  Since only the sensitized 
Cdk1 was able to use N6-(benzyl) ATP, only proteins that were substrates of 
Cdk1 were labeled with radioactive phosphate, allowing their isolation and 
identification. 
 The Bump and Hole approach has proven applicable to a variety of 
proteins but it is not fully general.  Most obviously, it requires a molecule that 
binds to the wild type protein to use as a starting point.  The binding pocket of the 
protein must also be amenable to mutations without drastically affecting the 
protein’s activity.  Furthermore, especially for animal studies, the modification of 
the drug may hamper its pharmokinetic properties.  As a more practical concern, 
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many biology labs lack the synthetic capabilities to synthesize the drug analogs 
and many chemistry labs lack the molecular biology knowledge to generate the 
mutant proteins, limiting the accessibility of the technique. 
 
Section 1.3 Controlling Dimerization 
 
 A wide variety of proteins are naturally regulated through dimerization. The 
fact that the dimerization domain or surface is normally distinct from the 
functional domain of a protein has been exploited to experimentally control these 
proteins in two main ways.  The first is the use of dominant negative proteins or 
peptides that contain the dimerization surface but not the functional domain.  The 
dominant negative species can bind to the wild type monomers, preventing them 
from forming productive dimers.  Dominant negative alleles of this variety can be 
found through mutagenesis screens, but some have also been rationally 
designed. 
 Perhaps the earliest report of this approach was by Laudano and Doolittle 
when, in 1980 they described the design and synthesis of peptides based on the 
N-terminus of fibrin that bound to and prevented the polymerization of fibrin [44].  
Fibrin is formed by thrombin proteolysis of fibrinogen.  Fibrin monomers 
spontaneously polymerize and are crosslinked by Factor XIII to form blood clots.  
The peptides synthesized by Laudano and Doolittle masked the binding surface 
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of a fibrin monomer, capping it and disrupting the poymerization process, 
effectively halting clotting. 
 The platelet derived growth factor (PDGF) receptor forms dimers upon 
binding to PDGF.  The intracellular tyrosine kinase domains then cross-
phosphorylate one another leading to receptor activation and signaling. Ueno, et. 
al. generated a dominant negative mutant simply by removing the intracellular 
domain [45].  Since a PDGF monomer is not able to phosphorylate itself, this 
truncated PDGF receptor was able to knock-out wild-type PDGF receptor activity 
by forming non-productive dimers in which tyrosine phosphorylation could not 
occur.  In a similar study, Kirschner and coworkers generated a dominant 
negative fibroblast growth factor (FGF) receptor by deletion of the intracellular 
tyrosine kinase domain [46].  Xenopus embryos expressing the truncated FGF 
receptor displayed developmental defects in mesoderm formation due to an 
inhibition of FGF signalling. 
 The design of dominant negative like alleles continues to grow in 
sophistication.  In recent work, Degrado and coworkers used computer modeling 
to design transmembrane helical peptides that could tightly bind cellular 
transmembrane helices and disrupt their interactions with other proteins [47].  
These peptides were used to generate a dominant negative ToxR in bacteria by 
preventing its productive dimerization.  They could also be used to disrupt the 
intramembrane interaction between two integrin subunits, which in the case of 
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integrins actually results in their activation.  So in some cases, a dominant 
“negative” can actually be an agonist rather than an antagonist. 
 The second widely used approach to control proteins by affecting their 
dimerization is the use of Chemical Inducers of Dimerization (CID).  CIDs are 
small molecules that have two protein binding surfaces and are thus able to bind 
to two separate proteins simultaneously, inducing their dimerization (Figure 1-4).  
When the domains that bind to a CID are expressed as fusions with other 
proteins, the fusion proteins can also be induced to dimerize, allowing their 
function to be controlled in a variety of ways. 
 In work published in 1993, Schreiber, Crabtree and coworkers used 
chemically induced oligomerization to activate the T-cell antigen receptors [9].  
Antigen receptors are naturally activated by binding to foreign antigens that are 
presented on the surface of antigen presenting cells.  Binding leads to 
aggregation of the receptors and intracellular signaling events which govern the 
immune response.  The ζ-chain of the antigen receptor was fused to a 3 copies 
of the FKBP domain.  The FKBP domain dimerizes in the presence of the CID 
FK1012, so the addition of FK1012 led to the oligomerization and activation of 
the modified receptors.   
 A similar approach was used to investigate the role of the Fas receptor in 
apoptosis.  The Fas receptor is involved in inducing apoptosis in B and T cells.  
Mice without functional Fas have excess, abnormal B and T cells and an 
autoimmune syndrome that is similar to lupus.  A fusion of a myristoylated 
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intracellular Fas domain and FKBP was generated that was dimerized and 
activated with FK1012.  By doing so, it was demonstrated that dimerization is 
necessary and sufficient to trigger apoptosis.  The conditional Fas allele was also 
used in transgenic mice to show that Fas only plays an apoptotic role in CD4+ 
CD8+ cells [11, 28].  The authors followed up this work by designing and 
synthesizing a novel CID/dimerized protein pair, namely a covalent dimer of 
Cyclosporin A, which can dimerize cyclophilins [48].  This system was also able 
to induce apoptosis through dimerization of the Fas receptor. 
 The power of CIDs is that with a little imagination, they are not limited only 
to the regulation of proteins that are naturally controlled through dimerization.  
Many transcription factors have a modular architecture in which DNA recognition 
and binding and transcriptional activation or inhibition are carried out by separate, 
autonomous domains [49, 50].  In fact, some transcription factors do not even 
exhibit DNA binding on their own, rather, they bind to other proteins which either 
directly or indirectly bind to DNA.  Often, all that is really required for 
transcriptional activation is to bring the activation domain close enough to the 
DNA to allow the recruitment of the RNA polymerase machinery.  This feature 
has been exploited in two-hybrid screens to identify protein-protein interactions 
[51, 52], and has also allowed the widespread use of CIDs to activate 
transcription factors.  A number of CID inducible transcription factors have been 
reported, in systems from bacteria to monkeys and with a variety of CIDs.  
Furthermore, because of the modular nature of transcription factors, the 
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activation domain of one transcription factor can be dimerized with the DNA 
binding domain of another and still be able to effect gene expression, further 
increasing the versatility of the system [12].  Looking at a cell through a high 
powered microscope, it is easy to get lost in the multitude of organelles and other 
substructures, small and large.  Sometimes activating a protein is a simple matter 
of helping it find where it is supposed to be in the mazelike cellular milieu.  The 
Src family of tyrosine kinases require membrane proximity for activity.  Schreiber 
and Crabtree were able to use their FKBP-FK1012 system to selectively activate 
Src kinase by inducing the dimerization of a membrane anchored FKBP and an 
FKBP-Src that lacked a myristoylation sequence [13].   
Cdc42 is a Rho GTP-binding protein that controls actin through the actions 
of the Wiskott-Aldrich syndrome protein (WASP).  The Chavrier group generated 
conditional alleles of both Cdc42 and WASP by CID mediated recruitment to the 
plasma membrane [53].  A chimeric receptor of the transmembrane and 
extracellular portions of the CD25 receptor and two copies of FKBP was made.  
Cdc42 or WASP were expressed as fusions with FRB.  The addition of 
rapamycin caused Cdc42 or WASP to localize to the cell membrane, resulting in 




Figure 1-4 : Sample CIDs and their targets.   Shown here are the 
structures and protein targets of a number of CIDs.  Some are natural 
products such as rapamycin and FK-506, others are artificial fusions 
between small molecules such as FKCsA [54] and Dexa-MTX [55]. 
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Proteins destined for the cell surface or secretion traffic through the Golgi 
apparatus where they acquire a number of post-translational modifications.  
Many of the Golgi resident enzymes responsible for these processes display 
modular architecture with a transmembrane domain responsible for localization 
and a catalytic domain that carries out the post-translational modification.  The 
Bertozzi lab took advantage of this property to generate a CID controlled protein 
allele of a fucosyltransferase [14].  The transmembrane domain was fused to 
FKBP and the catalytic domain to 3 copies of FRB.  Cells expressing these 
constructs displayed rapamycin dependent protein glycosylation.  This method 
was also shown to work on golgi sulfotransferases [15]. 
A remarkable feature of some proteins is that they can be split into inactive 
fragments, but upon forced dimerization, the fragments can refold and regain 
activity, a phenomenon known as protein complementation.  Protein 
complementation of fluorescent or luminescent proteins as well as those required 
for cell survival is often used as an indicator of protein-protein interactions[56].  
Proteins that are capable of complementation, can also be fused to dimerization 
domains such as FKBP and FRB and activated by the addition of a CID.  A 
number of conditional protein alleles have been generated this way, including 
GFP [17-20], luciferase [21, 22], β-lactamase [23, 25, 27], β-galactosidase [24], 
ubiquitin [16] and dihydrofolate reductase [26]. 
Although dimerization has been exploited in a number of creative ways to 
control protein function, a conditional allele for every protein cannot be generated 
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by controlling dimerization.  Dominant negative alleles are limited to proteins that 
are naturally regulated by dimerization.  In order to make a CID dependent 
protein allele, the protein must be generated as a fusion with the dimerization 
domains which may affect the protein’s activity.   Additionally, every CID 
dependent protein allele must be independently designed as there is no 
completely general way to activate a protein through dimerization. 
 
Section 1.4 : Controlled Degradation 
 
 An underappreciated means by which the cell regulates protein activity is 
through protein degradation, usually via the ubiquitin/proteasome pathway.  For 
example, Drosophila are able to adjust their circadian rhythms to the rising and 
setting of the sun through the light mediated degradation of the TIMELESS 
protein [57].  Salmonela confine the membrane ruffling effects of the SopE 
protein to a narrow time window with an N-terminal domain that targets the 
protein for rapid degradation [58].  Defined more broadly to include partial as well 
as complete proteolysis, partial degradation is used to control such proteins as 
the caspases [59] and signaling molecules such as the NFκβ family [60].  
 Protein stability can be exploited to gain experimental control over protein 
activity.  In 2000, Howley and coworkers demonstrated that proteins could be 
destabilized by fusion to a domain that is targeted by the cell’s ubiquitination 
machinery [61].  The Crews and Deshaies labs exploited this finding to generate 
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conditional protein alleles using a system they have termed PROteolysis 
TArgeting Chimeric moleculeS (PROTACS) [29].  In PROTACS, engineered CIDs 
recruit ubiquitin ligase to the targeted protein, resulting in its ubiquitination and 
subsequent degradation.  In some cases, the targeted protein has a substrate 
that can be incorporated into the chimeric molecule, allowing a traceless 
knockout.  If not, the target protein can also be generated as a fusion with a 
ligand binding domain. The Church lab has also described a similar method of 
targeted degradation [62]. 
Crabtree, Wandless and coworkers have also used protein stability to 
control protein acivity, but in the opposite way.  An unstable, mutant FRB domain 
(FRB*) was fused to a variety of proteins resulting in their degradation.  However, 
when the FRB* domain is bound to rapamycin and cellular FKBP, it adopts a 
stable, folded conformation.  The rapamycin induced stability of FRB* also 
stabilizes the target protein allowing it to build up and generate activity [30].  This 
technique was used to activate GSK-3β during defined 48 hour periods in 
developing mice embryos, defining a role for GSK-3β in both hard palate and 
sternum formation [31]. 
Wandless and coworkers have reported a further refinement of the 
system.  Instead of using a destabilized FRB*, a destabilized FKBP* was 
developed [32].  Proteins containing an FKBP* are degraded in a similar manner 
to those with FRB*.  However, rather than requiring dimerization with cellular 
FKBP for stabilization, the FKBP* is directly stabilized through binding to an 
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engineered ligand that was also developed by the Wandless group.  The 
resulting, stabilized protein is more similar to the wild type protein and is thus 
likely to behave in a more natural manner. 
Chemically controlled degradation has the potential to be at least as 
generally applicable as techniques such as RNAi.  PROTACS, FRB* and FKBP* 
have all been applied to multiple proteins and as more labs begin using the 
technologies will no doubt be applied to many more in the future.  Unfortunately, 
a traceless method of conditional degradation is not yet available.  In some 
cases, a natural ligand can be incorporated into a chimeric molecule allowing 
PROTACS on a wild type protein, but for the most part PROTACS requires the 
target protein be tagged with a ligand binding domain.  Both FRB* and FKBP* 
based protein alleles, of course, require tagging the target protein with the 
destabilization tag.   
 
Section 1.5 : Hormone Receptor Ligand Binding Domains 
 
 In 1988, Yamamoto and coworkers described an artificial transcription 
factor made by the fusion of the steroid binding domain of the glutocorticoid 
receptor with the E1A adenovirus transcription factor [63].  In the absence of 
hormone binding, the artificial transcription factor is bound by HSP90 and 
associated proteins, inhibiting activity.  Following binding to Dexamethasone, the 
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fusion protein dissociates from the HSP90 complex and regains activity (Figure 
1-5A).   
 Since then, a variety of conditional protein alleles have been generated 
through fusion to hormone receptor ligand binding domains, from a wide array of 
transcription factors, to kinases and β-galactosidase [64].  Two more recent 
examples are particularly interesting since they can be used to indirectly 
generate conditional alleles of other proteins. 
 The development of Cre and Flp recombinase based transgenics has 
allowed the generation of specific knock-outs and knock-ins in mice and yeast.  
Despite the versatility of such techniques, they are still limited in their temporal 
precision.  The placement of Cre recombinase under a tissue or development 
specific promoter can improve the spatial and temporal resolution of the knock-
out, but this strategy is limited by the available promoters.  In 1995, Chambon 
and co-workers described a Cre recombinase • ER-LBD fusion that was active 
only in the presence of 4-hydroxytamoxifen [33] (Figure 1-5B).  Since then, other 
Cre • HR-LBD fusions have been made, responsive to a variety of steroids [34, 
35, 65-67].  Similar work has been performed on Flp recombinase for use in 








Figure 1-5 : Generating conditional protein alleles by fusion to hormone 
receptor ligand binding domains.  (A) The target protein is expressed as a 
fusion with a hormone receptor ligand binding domain (HR-LBD).  In the absence 
of hormone binding, the target protein is rendered inactive through binding to 
HSP90 and associated proteins.  Hormone binding causes dissociation from the 
HSP90 complex, producing an active protein.  (B)  Fusion of CRE recombinase 
to the estrogen receptor ligand binding domain (ER-LBD) allows gene 
recombination to be triggered by tamoxifen.  (C)  Insertion of the ER-LBD into an 




Figure 1-5 : Generating conditional protein alleles by fusion to 
hormone receptor ligand binding domains.   
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 Intein mediated protein splicing and the related Expressed Protein Ligation 
(EPL) have already become widely used for biochemical preparations[70, 71].  
Since protein splicing results in a dramatic change in primary protein sequence, it 
has attracted interest as a means of generating conditional proteins alleles.  
Unfortunately, intein splicing does not appear to be regulated.  The Liu group 
generated a chemically controlled intein by the insertion of the ER-LBD into the 
RecA intein [36].  The resulting intein fusion required tamoxifen binding for 
activity and, when inserted into other proteins was able to generate conditional 
alleles of a variety of proteins. 
 Fusion with a hormone receptor ligand binding domain can imbue proteins 
of many classes with small molecule sensitivity.  Unfortunately, the ligand binding 
domain remains fused to the protein which, as with other techniques that require 
a tag, may or may not affect the target protein’s activity.  Additionally, the 
unliganded LBD does not directly inactivate the target protein, rather it recruits 
the HSP90 apparatus which may not fully inactivate the target protein.  The 
conditional intein described by Liu has the advantage that the LBD is removed 
during splicing, leaving a wild type or nearly wild type protein.  Splicing, however, 






Section 1.6 : The need for a general, traceless conditional allele 
 
 To be truly confident in the validity of the phenotypes generated with a 
conditional allele, the protein must be as close to wild-type as possible.  
Otherwise, a variety of controls must be performed to ensure that what is being 
analyzed is not, in fact, a conditional mutant allele.  Most of the techniques 
described above generate tagged proteins rather than wild-type proteins.  In 
some cases, such as degradation from FKBP* the tag is relatively small and 
presumably have relatively minor effects, but larger tags can be cause for 
concern. 
 Ideally, a technique for manipulating protein function should be so 
straightforward and general that it can be used as “kit” science – a box with a 
vector, an aliquot of the drug and an instruction manual that any lab can pick up 
and, after a few subclonings be able to control their favorite protein in a rapid, 
dose dependent manner.  Unfortunately, many of the methods described above 
do not fall into this category.  With the possible exceptions of the FRB*/FKBP* 
controlled degradation systems, the design of a conditional protein allele has to 
be performed on a case by case basis and may not work at all. 
 Much of my thesis work has been spent developing methods of generating 
conditional protein alleles with special emphasis on minimizing the differences 
between the conditional and wild type alleles and on maximizing the generality of 
the technique.  I have exploited two techniques for this purpose.  The first, 
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conditional protein splicing (CPS) uses a split intein to splice together two 
inactive fragments of a protein to generate an active protein.  This technique has 
the advantages of being nearly traceless and very fast, but unfortunately suffers 
from a lack of easy generality.  The second technique relies on ubiquitin 
complementation to release a protein from a degradation tag, resulting in its 
stabilization and activity.  This technique has the advantages of being easily 
generalized and traceless although, since it relies on protein translation to build 
up activity, it is not as fast as CPS based protein activation.  CPS will be 
discussed in Chapter 2.  Controlled protein degradation will be discussed in 
Chapter 3. 
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Chapter 2 : Conditional Protein Splicing 
This work was performed in collaboration with Lino Saez and Michael 
Young of The Rockefeller University. 
Section 2.1 : Introduction 
 
 Control over the timing, location and level of protein activity in vivo is 
crucial to a full understanding of biological function [1]. Living systems are able to 
respond to external and internal stimuli rapidly and in a graded fashion. One 
method by which the cell can achieve this is by maintaining a pool of proteins 
whose activity is altered through post-translational modifications [72]. In this 
manner, cells can adapt to environmental cues within minutes or even seconds. 
Thus, one means by which precise experimental control over cellular processes 
could be achieved is by directly altering post-translational protein modifications.  
Here we show that the post-translational process of protein trans-splicing [73] 
can be used to modulate enzymatic activity both in cultured cells and in an 
animal, specifically, Drosophila melanogaster. An optimized conditional protein 
splicing [74] (CPS) system was used to trigger the in vivo ligation of two inactive 
fragments of firefly luciferase. Enzymatic activity generated by trans-splicing 
appears rapidly and is tunable. This system provides a means of controlling 
enzymatic function with greater speed and precision than with standard genetic 
techniques and represents a useful tool for probing biological processes. 
 
 32 
Section 2.1.1 : Protein splicing 
 
 Protein Splicing is a post-translational process in which a protein domain 
known as an “intein” is able to effect its own removal from a polypeptide and 
splice together the flanking regions or “exteins” with a native peptide bond [70, 
71, 73, 75].  Over 350 intein or intein like proteins domains have been identified, 
from a variety of archae and eubacteria as well as in lower eukaryotes such as 
yeast [76].  Inteins have not been found in multicellular organisms although they 
bear some similarity to the hedgehog autoprocessing domain [73].  The 
machinery required for the splicing reaction is contained almost entirely within the 
intein, requiring only an additional cysteine or serine at the N-terminus of the C-
extein (Figure 2-1).  As such, inteins can be inserted into a variety of proteins 
without affecting the splicing reaction. 
 The relative promiscuity of inteins has allowed them to be exploited for a 
variety of biochemical purposes [70].  Mutant inteins which do not splice but 
rather exhibit N- or C-terminal cleavage can be used to purify recombinant 
proteins.  The recombinant protein is expressed as a fusion with an affinity tag 
and a mutant intein.  The affinity tag is used to immobilize the protein on a 
column.  Following intein cleavage, the recombinant protein is released from both 
the column and the affinity tag, allowing the elution of a pure recombinant protein. 
 Since the mutant inteins can be cleaved by thiolysis, they can be used to 
generate recombinant proteins with a C-terminal thioester.  This allows the facile 
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generation of proteins that can participate in the native chemical ligation (NCL) 
reaction [77].  In NCL, an N-terminal cysteine from one polypeptide selectively 
reacts with a C-terminal thioester from another polypeptide to generate a native 
peptide bond, joining the two polypeptides together.  When one or both of the 
polypeptides is a recombinantly expressed protein, the NCL reaction is known as 
Expressed Protein Ligation (EPL) [78]. 
  EPL has proven tremendously versatile for the site or domain specific 
incorporation of a wide variety of moieties [71].  If one of the two ligation 
fragments is made synthetically, nearly anything can be incorporated at any site 
in that piece.  Ligation fragments that are expressed recombinantly can also be 
modified – either globally by changing the growth conditions of the cells or more 
specifically by chemically modifying the protein after expression.  The site or 
domain specific modifications that can be made to proteins through EPL are 
limited only by imagination.  To name a few, isotopic labels, fluorescent tags, 
phophorylation, ubiquitination, photocages, and unnatural amino acids have all 
been specifically incorporated into proteins using EPL [71, 75]. 
 A remarkable subset of inteins have been identified which, rather than 
splicing in cis, splice in trans [73].  The intein itself has been split into two 
fragments during evolution, each of which is expressed, along with an extein as a 
separate protein.  The intein fragments have a high affinity for one another [79], 
however, and when present in the same cell are able to associate, re-fold and 
splice together their exteins.  In addition to the naturally split inteins that have 
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been identified, several inteins which normally splice in cis have been artificially 
split and shown to retain the ability to splice in trans.  However, artificially split 
intein fragments have only a weak affinity for one another and thus, in order to 
force the trans-splicing reaction to occur, very high concentrations of protein are 
required. 
 Nonetheless, trans-splicing has found a place in the biochemist’s toolbox.  
The trans-splicing reaction can be used in a similar manner to EPL to generate 
semisynthetic proteins [75].  The obvious drawback to using trans-splicing 
instead of EPL is that the intein must be incorporated into the protein fragments.  
This is trivial when expressing the proteins recombinantly, but can be challenging 
when done synthetically.  However, since the split intein fragments can only react 
with their complemenatary intein fragment (indeed, even fragments from different 
inteins will not react with one another) the trans-splicing reaction can be 
performed in crude cell lysates [79] and even in living cells [80] without the need 




Figure 2-1 : The protein splicing mechanism. 
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Section 2.1.2 : Controlling protein splicing 
 
 The dramatic changes in sequence and structure that accompany splicing 
can affect the activity of a protein, but since inteins themselves are not regulated, 
this is of little experimental utility.  As a result, there has been some effort put into 
generating conditional inteins that can in turn be used to conditionally activate or 
inactivate a target protein. 
 Adam and Perler have developed a temperature sensitive (TS) intein by 
inserting the Mycobacterium GyrA intein into E. coli DNA gyrase and screening 
for splicing at restrictive temperatures [81].  The Perrimon group has also 
reported a TS intein [82].  A library of intein mutants was screened for splicing at 
different temperatures resulting in the isolation of an intein that splices efficiently 
at 18 °C but not at 30 °C.  This TS intein was used to generate TS alleles of Gal4 
and Gal80.  When used in combination with Gal4 enhancer trap lines, this allows 
the control of a wide array of genes’ activities with simple temperature shifts in 
both cultured cells and living Drosophila.   
 As noted in chapter 1, the Liu group has developed an Estrogen Receptor 
Ligand Binding Domain (ER-LBD)-intein fusion in which the intein’s activity 
requires the binding of tamoxifen to the ER-LBD (Figure 1-5C).  The ligand 
binding domain of the ER was inserted into the RecA intein.  The ER-intein fusion 
was then mutagenized by error prone PCR and subjected to screening and 
selection to evolve intein splicing only in the presence of 4-Hydroxy-tamoxifen.  
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The tamoxifen sensitive intein has been used to generate a variety of conditional 
protein alleles, including GFP, β-galactosidase, and the transcription factors Gli1 
and Gli3T [36, 37]. 
Previous members of the Muir lab had developed a Conditional Protein 
Splicing (CPS) system in which fragments of an artificially split S. cerevisieae 
vacuolar ATPase (VMA) intein complement through rapamycin induced 
heterodimerization of the FKBP and FRB proteins (Figure 2-2A).  The original 
CPS report demonstrated the rapamycin triggered splicing of the purified model 
proteins MBP and Hisx6 [74].  This was rapidly followed up by a report in which 
the process was shown to work in cultured mammalian cells [83].  The process 
was also shown to be rapid and dose dependent.  In later work, the activity of 
purified protein kinase A was modulated using CPS [84].  A modified protein 
kinase A was generated as a fusion with the C-terminal CPS cassette and a 
substrate mimic peptide inhibitor (Figure 2-2B). Although the peptide inhibitor 
has a relatively weak KI, since it is tethered to the kinase, it is able to efficiently 
inhibit enzymatic acitivity.  Following either splicing or C-terminal cleavage, the 
inhibitor is released from the kinase, allowing it to recover activity.  Finally, CPS 
has been used in conjunction with the naturally split DnaE intein to perform 3 
piece protein ligations for biochemical studies [79]. 
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Figure 2-2 : Conditional Protein Splicing.  (A) Fragments of the S. 
Cerevisiae VMA intein (IN and IC) are fused to the FRB and FKBP domains 
and to two proteins or peptides (N-extein and C-extein).  In the presence 
of rapamycin, FKBP and FRB dimerize, which brings the intein fragments 
together, thereby leading to complementation and splicing.  (B) CPS has 
been used to activate an auto-inhibited kinase.  Protein Kinase A (PKA) 
was generated as a fusion with FRB, the C-terminal intein fragment (Ic) 
and a peptide inhibitor of PKA.  Upon splicing, PKA was released from the 





Section 2.2 : Results 
Section 2.2.1 : Generating conditional protein alleles with CPS 
 
We were interested in using CPS as a general means of producing 
conditional protein alleles both in cultured cells and in living animals.  The only 
other use of CPS to regulate protein activity was the auto-inhibited kinase 
described above.  Unfortunately, this method could not be applied to proteins 
which could not be reversibly inhibited in cis by a peptide.  Additionally, although 
this may be because of the kinase chosen, CPS regulation of protein kinase A 
was never successfully performed in cultured cells, much less in living animals. 
We reasoned that the most general way of inactivating a protein would be 
to split it into fragments.  Upon splicing, the full length, wild type protein would be 
regenerated as well as, presumably, activity.  To test this, we chose firefly 
luciferase as a model enzyme.  Luciferase has a number of attractive features for 
developing and optimizing CPS as a means of generating conditional protein 
alleles[85].  The bioluminescent activity of luciferase is easily detected and 
quantified allowing one to quickly determine if the system was working and with 
what efficiency.  Luciferase requires no post-translational modifications for 
activity, so it should be active as soon as it has refolded following splicing.  
Finally, since luciferase is a monomeric protein, we would not have to worry 
about potential dominant negative effects from unspliced luciferase fragments. 
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Figure 2-3 : Design of a conditional allele of luciferase.  (A)  Space-
filling models of firefly luciferase depicting the different splicing sites we 
tested.  The N- terminus of luciferase is in red, the C- terminus is in blue, 
and splice sites are indicated by arrows.  Also shown is the structure of 
the VMA intein with the active splicing residues shown in magenta (N-
terminus, orange; C-terminus, green).  We did not observe splicing from 
the split at Arg437, but we were able to generate conditional splicing at 
Lys491.  (B)  The constructs used in this study.  In N-luc, the N-extein (LN) 
is luciferase1-490 with the mutation H489K.  In C-luc, the C-extein (LC) is 
luciferase491-551 with the mutation K491C and tandem copies of FRB 
(FRB(n), where n = 1-3). 
   
When deciding where to split luciferase for the generation of a CPS based 
conditonal protein allele, we were aided by the fact that a crystal structure has 
been determined.  Luciferase is a 61kDa monomeric protein made up of a large 
N-terminal lobe and a small C-terminal lobe (Figure 2-3A). Another group had 
reported protein trans-splicing on luciferase using a different intein by splitting the 
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protein in between the N- and C-terminal lobes. Thus, we initially split the protein 
at the same site, residue Arg437. Surprisingly, despite robust expression in 
Drosophila (Schneider’s line 2, S2) cells, no trans-splicing or luciferase activity 
was observed (Figure 2-4). Modeling studies suggested that steric crowding 
within the trans-splicing complex might account for the lack of splicing and 
enzymatic activity (Figure 2-3A); each structured component would act like a 
wedge preventing functional complementation of the other. Consistent with this, 
the construct encoding luciferase 437-551 was able to splice with other proteins 
such as MBP (Figure 2-5). 
With this in mind, we returned to the crystal structure to design a new split 
site.  We reasoned that since it was likely the tertiary structure of luciferase that 
was interfering with the complementation and splicing of the intein, the split site 
should be chosen to minimize the interaction between the intein and luciferase.  
This led us to choose Lys491, which is located on a surface exposed loop within 
the smaller C-terminal lobe (Figure 2-3A) and should be compatible with the 
presence of the folded intein. This gave rise to the CPS constructs referred to as 
N-luc (encoding (Flag)-(Luciferase[1-490])-(N-VMA)-(FKBP))  and C-luc 








Figure 2-4 : Attempted splicing at luciferase R437. Attempts to splice 
at Luciferase R437.  (A) Drosophila S2 cells were transfected with 
constructs encoding Luciferase1-436 (D436G) – N-VMA – FKBP and FRB 
– C-VMA – Luciferase 437-551 (R437C) and allowed to express for 40 
hours. Cells were then treated with 0.1% DMSO (D) or with 1 mM 
rapamycin (R) for 5 h before being analyzed by western blot using an anti-
luciferase antibody.  The molecular weight of luciferase is 60.7 kDa.  (B) 
Drosophila S2 cells were transfected with the indicated plasmids and a 
renilla luciferase transfection control. Following 16 hours of expression, 
cells were treated with 0.1% DMSO or rapamycin to a final concentration 
of 100 nM and 0.1% DMSO.  Rapamycin treatment was allowed to 
proceed for 4 hours before cells were harvested and assayed for 
chemiluminescence. A CPS inducible split luciferase (N-luc and C-luc) was 











Figure 2-5 : Splicing of Luc 437-551 with Maltose Binding Protein 
(MBP). Constructs encoding Luc 437-551 and one encoding MBP-IN-
FKBP (MBP) under the control of the heatshock promoter were used to 
transfect S2 cells.  Two days after transfection, cells were incubated at 37 
°C for 5 minutes followed by 5h at room temperature.  Cells were then 
treated with 0.1% DMSO or 100 nM rapamycin for 2h then harvested and 




Figure 2-6 : Splicing and activation of luciferase in cultured cells.  
Drosophila S2 cells were transfected with the indicated constructs and 
treated as described in Figure 2-4b (A) Western blot using an anti-
luciferase antibody against lysates from cells treated with DMSO (D) or 
rapamycin (R). Loading was normalized through renilla luciferase activity 
levels.  (B) Luciferase activity in cell lysates expressed as a ratio between 
firefly luciferase activity and renilla luciferase activity.  Error bars represent 
standard deviation (n=3). The mutant N-Luc and C-Luc constructs contain 
inactivating C1A and N454A mutations, respectively. 
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 Cultured S2 cells were transfected with N-luc and C-luc.  Following protein 
expression, cells were treated with rapamycin or DMSO vehicle.  Western 
blotting confirmed the rapamycin dependent generation of full-length luciferase 
(Figure 2-6A).  However, since presumably the split at Lys491 would result in an 
unfolded C-terminal lobe, it was quite possible that the splice product would not 
have enzymatic activity. 
To determine if the spliced luciferase could fold and gain enzymatic 
activity, S2 cells expressing N-luc and C-luc were treated with rapamycin and 
assayed for luciferase activity. As expected, neither luciferase fragment displayed 
any enzymatic activity on its own (Figure 2-6B). However, when cells expressing 
both N-luc and C-luc were treated with rapamycin, luciferase activity increased 
dramatically (Figure 2-6b), and in a dose-dependent manner (Figure 2-7). In 
order to control for possible differences in transfection efficiency, firefly luciferase 
activity was normalized to renilla luciferase activity, which was co-transfected. To 
avoid potential complications from rapamycin side effects, we also tested a 
rapamycin analog (AP21967, Ariad).  The rapamycin analog and the FRB 
(containing the mutation T2098L) used in this study were designed using the 
bump and hole approach described above.  The modified rapamycin is able to 
bind to the mutant FRB, but not to the native TOR protein, preventing off target 
effects.  The rapamycin analog was able to induce splicing nearly as well as 
rapamycin (Figure 2-7). 
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Figure 2-7 : Dose dependence of splicing in response to rapamycin 
or rapamycin analog. S2 cells were transfected with N-luc and C-luc as 
well as renilla luciferase transfection control. After 16 hours, cells were 
treated with the indicated level of rapamycin or rapamycin analog (Ariad 
AP21967). After 4 hours, cells were assayed for luciferase activity and 
plotted against the level of luciferase activity in cells treated with DMSO 
control. Error bars represent standard deviation (n = 3-4, except 100 pM 
and 5 mM data points where n = 2). 
 
To ensure that the observed luciferase activity was due to protein splicing 
and not complementation of the luciferase fragments, we generated versions of 
N-luc and C-luc with intein mutations rendering them splicing incompetent.  Two 
residues are required for the splicing reaction – the first (cysteine) and last 
(asparagine) residues of the intein (Figure 2-1).  By mutating these to alanine, 
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the N-S acyl shift and the transthioesterification steps are blocked, preventing 
splicing.  No significant splicing or chemiluminescence activity could be detected 
from cells expressing these mutant constructs, either with or without rapamycin 
treatment (Figure 2-6B). Thus, splicing is necessary for the generation of 
luciferase activity, and the small amount of luciferase activity observed when the 
N-luc and C-luc constructs are co-expressed is due to a low level of rapamycin-
independent splicing. 
Although rapamycin increased luciferase activity by more than an order of 
magnitude, we wanted to improve the ratio of induced to background splicing.  
There were two main ways we could go about this – attempting to improve the 
splicing reaction itself or improving the association between the two fragments.  
We chose to try to optimize the splicing reaction through temperature effects and 





Figure 2-8 : Optimization of the luciferase CPS system. (A) The effects 
of temperature on the splicing reaction.  S2 cells transfected with N-luc 
and C-luc were incubated for 6h at 25 °C and then transferred to the 
indicated temperature for 10h. Cells were then treated with 0.1% DMSO or 
100 nM rapamycin for 4h at the indicated temperature before being lysed 
and assayed for luciferase activity. (B) Effect of multiple copies of FRB on 
the induction of luciferase activity.  S2 cells were transfected with N-luc 
and C-luc with 1-3 copies of FRB.  Following 16h of gene expression, cells 
were treated with 0.1% DMSO or 100 nM rapamycin for 4 hours and then 
assayed for luciferase activity. (C) Kinetics of activation through splicing. 
S2 cells transfected with N-luc and C-lucFRB2 were treated with 0.1% 
DMSO or 100 nM rapamycin after 16h of gene expression. Cells were 
harvested at the indicated time points and assayed for luciferase activity. 
(D) Use of ascomycin competition to regulate splicing.  S2 cells expressing 
N-luc and C-lucFRB2 were treated with 0.1%DMSO or 5 nM rapamycin.  
Ascomycin was added to a final concentration of 500 nM, 15 minutes or 1 
hour after rapamycin treatment without washing out the rapamycin. Cells 
were harvested at the indicated time points and assayed for luciferase 







Figure 2-8 : Optimization of the luciferase CPS system. 
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The splicing efficiency of the VMA intein is known to be dependent on 
temperature [86, 87], so we reasoned that there may be an optimum temperature 
that minimized background splicing while still allowing rapamycin induced 
splicing.  N-luc and C-luc were co-expressed and the cells treated with rapamycin 
at different temperatures. Background splicing decreased with increasing 
temperature while the level of rapamycin induced luciferase activity was highest 
at 25 °C (Figure 2-8A and Figure 2-9). The ratio between background and 
rapamycin induced luciferase activity was highest at elevated temperatures, for 
example 6-fold at 21 °C compared to 22-fold at 28 °C. The lower levels of activity 
at elevated temperatures are likely due to S2 cell physiology. For example, 35 °C 
is not optimum for the growth of this cell line.  This is supported by the fact that 




Figure 2-9 : CPS activated luciferase in mammalian cells. N-luc, C-luc 
and C-lucFRB2 were cloned into the pCDNA3.1 vector (Invitrogen).  Hela 
cells were transfected with these constructs as well as pRL-SV40 (renilla 
luciferase control, Promega).  Following 16 h expression, cells were 
treated with DMSO or 100 nM rapamycin for 4 hours.  Cell lysates were 
then analyzed for luciferase activity. Luciferase activity increased 75 and 
130-fold with 1, 2 copies of FRB respectively. Error bars represent 
standard deviation. 
 
 Additional copies of the heterodimerization domains are known to improve 
rapamycin-induced association [9, 14]. Thus, we generated versions of C-luc 
containing 2 and 3 tandem copies of FRB (C-lucFRB2 and C-lucFRB3, Figure 2-
2C). In both cases, the level of rapamycin induced splicing over background was 
better than with a single FRB domain (Figure 2-8B). Luciferase activity increased 
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15, 50 and 75-fold over background with 1, 2 and 3 copies of FRB respectively. 
However, C-lucFRB3 expresses poorly (Figure 2-10), leading to very low levels 
of luciferase activity albeit with negligible background splicing. Thus, the C-
lucFRB2 construct was used for further characterization of the system, although 
for certain applications, the C-lucFRB3 version may be preferable. 
 
Figure 2-10 : Poor expression of C-lucFRB3.  Cells were transfected 
with the indicated constructs and treated as described in Figure 3.  Cells 
were analyzed by western blot using an anti-luciferase antibody.  C-
lucFRB3 should migrate above C-lucFRB2. 
 
One of the major advantages of small molecule based approaches is the 
speed with which they work.  To evaluate the kinetics of the CPS reaction, S2 
cells expressing N-luc and C-lucFRB2 were treated with rapamycin and 
monitored for luciferase activity at a number of time points over 24 hours. By 
fifteen minutes, the earliest time-point taken, luciferase activity increased by an 
order of magnitude over DMSO treated cells and continued to increase over the 
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next 24 hours (Figure 2-8C). Additional experiments were performed to examine 
whether the kinetics of splicing reactions could be tuned by adding a second 
small molecule, ascomycin, which acts as a competitive inhibitor of rapamycin 
induced dimerization [74]. S2 cells expressing N-luc and C-lucFRB2 were treated 
with rapamycin followed by ascomycin either 15 minutes or 60 minutes later. 
Addition of the antagonist led to the attenuation of trans-splicing (Figure 2-8D).  
Next, we asked whether the CPS approach would work in a living animal.  
Transgenic flies were generated containing genomically integrated copies of the 
luciferase CPS expressed under the control of the timeless promoter. Adult flies 
were placed in individual chambers with food containing luciferase substrate and 
either DMSO or rapamycin. Luminescence was then monitored for 1-2 days. 
Flies fed DMSO had very similar luminescence levels to non-transgenic flies, 
whereas flies fed rapamycin exhibited easily detected luciferase activity (Figure 
2-11A-B and Appendix 1). Western blotting confirmed the generation of full-
length luciferase upon feeding the transgenic flies rapamycin (Figure 2-12).  The 
jagged nature of the luciferase traces are a product of the assay since the same 
profile is seen with positive control flies expressing full-length luciferase under the 
control of the timeless promoter (Figure 2-11C and Appendix 1). Similar traces 
have been obtained in other studies using real time luciferase imaging in fruit 
flies[88, 89]. CPS induced luciferase activity could be detected by the time the 
first measurements were taken, as early as 10-20 minutes after flies were placed 
on rapamycin containing food. However, in some cases the kinetics were on the 
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order of a few hours, which likely reflects differences in feeding behavior 
(Appendix 1). CPS induced luciferase activity could also generated when the 
constructs were expressed under the control of the armadillo promoter, albeit 









Figure 2-11 : Activation of luciferase in living D. melanogaster. Flies 
were deprived of food for 1 hour before being anesthesized with CO2 and 
placed in individual chambers with food containing 200 µM luciferin and 
either 2% DMSO (light blue) or 100 µM rapamycin (dark blue). Luciferase 
activity was then monitored from individual flies every 12 minutes with a 1 
minute acquisition in a luminometer. (A) Non-transgenic flies (yw). (B)Flies 
expressing N-Luc and C-LucFRB2 under the control of the timeless 
promoter (yw;tim-Gal4,N-luc;C-lucFRB2). (C) Flies expressing full length 









Figure 2-12 : Generation of full length luciferase through CPS in adult 
Drosophila. Adult flies of genotypes yw;arm-Gal4,N-luc;C-luc (CPS), yw 
and tim-Luc;CyO;Sb/TM6 (Luc(wt)) were deprived of food for 1 hour and 
then placed on 3MM filter paper soaked in 40% glucose supplemented 
with 100 µM rapamycin (2% DMSO) for 12h.  Individual flies were 
homogenized in PLB with 1 mM ZnCl2. Protein concentration in fly lysates 
was determined by the Bradford assay (Biorad). 5 µg of total protein was 




Section 2.2.2 : How good is CPS at generating conditional protein alleles? 
 
As a means of generating conditional protein alleles, CPS has a number of 
attractive features.  First and foremost is the speed by which it functions. The 
induction of activity can occur in less than 15 minutes in both cultured cells and in 
living animals. By way of comparison, using the FKBP-FRB dimerization system 
to drive transcription through association of fragments of a transcription factor 
can take days to generate gene products in vivo. Speed also sets CPS apart 
from techniques that rely on protein stability as a mode of control since those 
processes are limited either by the rate of protein synthesis or degradation.   
Like most conditional protein alleles, those generated by CPS are 
titratable.  In the CPS system, activity levels can be in a variety of ways.  Most 
obvious is rapamycin dosage.  The use of ascomycin competition or temperature 
changes can further tune the response.  Finally, FRB copy number can be used 
to set the upper and lower limits of protein activity that will be generated. 
Another major advantage over many other techniques is the relatively 
traceless nature of the knock-in.  The final, spliced protein differs from wild-type 
luciferase in only 3 point mutations, only one of which we are certain is required 
for protein splicing and recovery of function.  Although a flag tag was added for 
the purposes of western blotting, this was simply for experimental convenience 
and likely could be removed without affecting the protein’s activity.  Although 
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admittedly a tag, no matter how big does not necessarily affect a proteins activity 
indeed, often does not, using a traceless technique such as CPS could serve to 
eliminate any concerns of non-wild-type activity from the start of an experiment. 
Unfortunately, where CPS falls short as a means of generating conditional 
proteins alleles is in its generality and its lack of reversibility.  Splicing can be 
attenuated by washing out rapamycin or by the addition of ascomycin, but it 
cannot be reversed.  Although splicing in cis has been reported to be almost 
completely promiscuous with regard to flanking extein sequences, our experience 
with conditional trans splicing has shown a very strong sequence dependence on 
splicing efficiency.  We have already mentioned above one luciferase splice site 
that was tried but failed.  In addition to this, 5 other splice sites were cloned and 
tested, only one of which worked (Figures 2-13 and 2-14). 
The most obvious difference between the site that worked (K491) and the 
site that failed (R437) is that the site that succeeded is located in a surface 
exposed loop while the one that did not is located between two folded lobes.  
Consistent with the idea that surface exposure is required for splicing to occur, 
the second site that successfully spliced (T508) is also located in a surface 
exposed loop.  However, a third surface loop residue (S185) was also tested and 
displayed neither splicing nor activity.  Thus, while surface exposure may be 








Figure 2-13 : Splicing at luciferase residue 508.  Drosophila S2 cells 
were transfected with the indicated constructs and treated as described in 
Figure 2- 4a.  (A)  CPS constructs of comprising luciferase 1-507 and 
luciferase 508-551 were able to splice in the presence of rapamycin to 
generate full length luciferase.  Luciferase 508-551 was also able to splice 
with a CPS construct encoding Maltose Binding Protein (MBP).  The 
constructs used for splicing at luciferase 491 and at luciferase 508 migrate 
almost identically on SDS-PAGE and are thus labeled only once as “N-luc” 
and “C-luc.”  (B)  Luciferase generated by the splicing of luciferase 1-507 
and luciferase 508-551 is active.  Raw luciferase counts are shown from 
equal volumes of lysate as the Renilla luciferase control was not yet 





Figure 2-13 : Splicing at Luciferase residue 508.     
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In addition to the 3 splice sites located in surface loops tested, one that 
was located in a surface helix (S298) and two that were located in the 
hydrophobic core of the protein (C81, C216) were also generated and all failed. 
This is despite the fact that in some cases, the expression of both fragments 
could be detected by western blot (Figure 2-14).  Interestingly, while in no case 
could splicing be detected by western blot, the C216 constructs displayed 
luciferase activity that was not dependent on the presence of rapamycin.  This 
may be the result of one of the fragments retaining some activity.  Alternatively, 
the two pieces may have an affinity for one another and may be able to 
spontaneously complement in trans. 
 
Figure 2-14 : Failed splicing at 4 split sites in luciferase.  S2 cells 
were transfected with constructs encoding CPS pairs split at the indicated 
residue and treated as described in Figure 2-4B.  Full length luciferase 
(WT) and the N-luc/C-luc CPS pair (491) used previously in this section 
are included as controls.  No splicing could be detected in any of the 
alternative splicing sites. 
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The original reason for attempting to use CPS in Drosophila was our 
desire to apply CPS to the study of circadian rhythms.  Circadian rhythms in 
Drosophila are regulated by a series of interlocking feedback loops which result 
in a tightly defined rise and fall in the level and activity of a number of proteins 
which in turn give rise to stereotyped 24 hour rhythmic sleep-wake cycle.  
Although genetic techniques have allowed the elucidation of many of the 
participating proteins as well as provided insight into how they interact to give rise 
to circadian rhythmicity, the lack of speed, tunability and reversibility of genetic 
methods have left many questions about circadian rhythms unanswered [57]. 
We reasoned that CPS would be ideal for the study of circadian rhythms.  
The speed with which it works would allow the manipulation of the cycling 
proteins faster than they naturally rise and fall.  For example, PERIOD or 
TIMELESS could be activated out of phase with the natural cycle.  The resulting 
phenotype would allow the determination of which, if any of these proteins is the 
actual “pace setter” of circadian rhythms.  Ideally, a non-natural sleep-wake cycle 
could be forced through the use of rapamycin, allowing elucidation of the 
molecular and cellular events that precede the sleep or wake phase. 
Alternatively, a number of the proteins involved, notably 
DOUBLETIME(DBT) [90, 91] and SHAGGY(SGG) [92] are necessary for normal 
development.  Null mutations of DBT and SGG are lethal, making it difficult to 
specifically study their roles in the regulation of circadian rhythms.  Since active 
protein is only generated in the presence of rapamycin, CPS could be used to 
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generate a delayed knockout of DBT or SGG.  Rapamycin, or more likely, 
rapamycin analog could be provided during larval growth but withheld from adult 
flies.  Presumably, drug metabolism and protein turnover would then result in an 
adult knockout of SGG or DBT allowing a more detailed study of the role that sgg 
and dbt play in circadian rhythms. 
Despite the difficulty in locating additional splicing sites in luciferase, we 
attempted to generate a CPS allele of DBT.  Unfortunately, the structure of DBT 
has not yet been determined making the design of a splicing site difficult.  DBT is 
a two domain protein [91].  The N-terminal domain is the fly homolog of casein 
kinase, of which a crystal structure has been generated and a C-terminal domain 
that bears no homology to any other sequence in the NCBI database (protein 
BLAST search http://www.ncbi.nlm.nih.gov) and is characterized by repetitive 
stretches of alanine, glycine and glutamine.  Compounding the difficulty in 
designing a splice site was the lack of a convenient and reliable in vitro or cell 
based assay for DBT function.  Since we would not be able to test the effects of 
any mutation made without generating a transgenic fly, we were reluctant to 
make many mutations, especially in the kinase domain in which many functional 
mutations have been isolated. 
 We chose 6 sites to attempt to splice DBT.  They fall into 2 categories – 
native cysteines that did not require mutation (C96, C267), and residues following 
a glycine that were mutated to cysteine (F282C, A311C, S352C, S376C, Figure 
2-15). Of these, only one (C96) was within the core of the kinase domain.  
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Unfortunately, in no case could full length DBT be generated through splicing, as 
analyzed by western blot (Figure 2-16). Interestingly, the C-terminal fragment of 
the C96 splice site appears to be able to splice with the N-luc fragment used for 
the Drosophila work, much like some of the luciferase fragments that could not 
splice with each other could splice with MBP or a Hisx6 tag. 
 
Figure 2-15 : DOUBLETIME. The protein sequence of DOUBLETIME 
(DBT).  Shown in blue is the region that shows sequence homology to 
casein kinase.  Shown in red is the region that has no homology to any 
sequence in the NCBI database.  Residues at which splicing was 
attempted are shown in bold, black letters. 
  
 In hindsight, DBT may have been a poor choice as the second target of 
CPS.  The lack of structural information has already been mentioned.  
Additionally, the C-terminal domain, which is required for DBT’s role in the 
regulation of circadian rhythms may have also been interfering with splicing.  The 
C-terminal domain’s sequence is unlike anything else in the NCBI database.  It 
likely has little to no secondary structure which may affect solubility and may be 
involved in protein-protein interactions which may affect the localization of the 
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CPS construct.  Perhaps in the future, when more is known about the rules 
governing CPS sites or when a structure of DBT is available, a CPS allele of DBT 










Figure 2-16 : Attempts to generate a conditional allele of DBT.  S2 
cells were transfected with the indicated CPS constructs.  All CPS 
constructs were generated as N-terminal MBP fusions for Western blotting 
purposes.  Following overnight expression, cells were treated with 0.1% 
DMSO or 100nM rapamycin for 24 hours.  Cells were then harvested and 
analyzed by Western blot (anti-MBP or anti-DBT as indicated).  Spliced 
DBT could not be detected in any of the samples. 
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Figure 2-16 : Attempts to generate a conditional allele of DBT.   
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Section 2.2.3 : Improving CPS for the generation of conditional protein 
alleles 
 
It is fairly clear that, while CPS is very powerful when successfully applied, 
it is difficult to apply it to new proteins.  One approach that we proposed to 
alleviate this difficulty was to generate a method to screen rapidly for new splicing 
sites.  Thus, rather than designing, cloning and testing each splice pair 
individually, one could start with a library of split protein pairs and simply screen 
for ones that exhibit rapamycin dependent splicing.  Unfortunately, one cannot 
simply generate an N-terminal fragment library and a C-terminal fragment library 
and then mix them together for the screen since this would result in the vast 
majority of splicing “hits” not generating wild type protein.  Indeed, our suspicion 
is that the majority of CPS partners found this way would be the result of splicing 
a small peptide from the N-terminus of the protein to a small peptide from the C-
terminus.  Thus, the library must be generated in a manner that the N-terminal 
fragment is genetically linked to the C-terminal fragment that encodes the 
remainder of the protein.   
There are two potential methods for creating a library of CPS constructs to 
screen for splicing – a transposon based screen and a circular permutation 
based screen (Figure 2-17 and Figure 2-18).  Neither is perfect – the 
transposon method necessarily adds flanking residues that are part of the 
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transposon itself, and the gel sizing step in the circular permutation method will 
result in proteins that are only approximately full length.  Nonetheless, at the very 
least, the screens should be capable of identifying regions of the protein that are 
amenable to intein insertion.  Given that the two luciferase splicing sites that 
worked were only 17 residues apart, finding such a region may be all that is 
needed to generate a CPS protein allele that results in wild type protein simply by 
removing or replacing the residues that are inserted or deleted in the library 
cloning.  
Although the generation of a screen would greatly streamline the 
application of CPS to new systems, screening for CPS sites in a new protein 
could still take a long time and ultimately be unsuccessful.   Unfortunately, it 
appears that there is and always will be a degree of sequence dependence in 
CPS which may not always be overcome.  As such, we turned to a new approach 




Figure 2-17 : A transposon screen for splicing sites. A high copy plasmid 
encoding for ampicillin resistance and the target gene will be mutagenized in vitro 
using the transposon CPS-Tn5.  Since Kanamycin nucleotidyltranferase 
(KNTase) is present as a C-terminal fusion, it will be correctly translated and 
confer kanamycin resistance only if N-VMA/FKBP is inserted in frame into a 
gene. Transformed bacteria will also acquire kanamycin resistance if the 
transposon inserts into the ampicillin resistance marker.  Thus, transformants will 








Figure 2-18 : A circular permutation screen for CPS sites.  In a 
circular permutation screen for CPS accessible sites, the target protein 
would first be cloned as a head to tail permutation.  DNA ligation will result 
in a circularized gene which is then randomly cut under single hit 
conditions with DNAse.  A gel sizing step then removes genes that have 
been cut multiple times.  The full length genes can then be inserted into a 
plasmid encoding the N- and C- CPS cassettes through blunt end ligation 




Figure 2-18 : A circular permutation screen for CPS sites. 
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Chapter 3 : Controlled Protein Degradation 
This work was performed in collaboration with Matthew Pratt of the 
Rockefeller University. 
 
Section 3.1 : Introduction 
 
The allele of luciferase that we generated using CPS was an almost 
perfect conditional allele.  The induction of activity was rapid and titratable, 
appearing within minutes and in a dose dependent manner.  The activated 
protein was virtually wild type, with only a few point mutations.  Finally, small 
molecule mediated protein activation was possible in a variety of contexts – 
cultured cells, both mammalian and insect as well as living Drosophila.  However, 
we were unable to generate a conditional allele of another protein using CPS, 
bringing the generality of CPS into question. 
 Taking advantage of this property of ubiquitin, we turned to an alternative 
strategy that takes advantage of endogenous cellular processes, by placing the 
stability of a protein of interest under pharmacological control.  Other work in this 
area was discussed in Section 1.4.   
 We reasoned that an ideal degradation-mediated technology would result 
in the release of a native protein from the degradation signal (or “degron”) 
following small molecule rescue of a chimeric protein-degron fusion.  To achieve 
release from the degron, we somewhat counter intuitively turned to a known 
mediator of protein degradation, ubiquitin.  Ubiquitin plays several roles in both 
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protein trafficking and stability, primarily through its posttranslational conjugation 
to lysine side chains of target proteins [93].  Unlike this branched ubiquitin 
structure, linear ubiquitin fusions are known to be translational products where 
the N-terminal ubiquitin moiety is rapidly and specifically cleaved from its fusion 
partner by dedicated ubiquitin proteases [94].  These proteases have broad 
specificity for the residues following ubiquitin, with proline being the only amino 
acid resistant to cleavage.  Johnsson and Varshavsky have utilized this feature in 
a two-hybrid technology based on complementation and subsequent cleavage of 
a genetically split ubiquitin [16].  Briefly, ubiquitin was split into N- and C-terminal 
fragments, corresponding to residues 1-37 and 35-76 respectively.  When a point 
mutation (I13G/A) was also introduced, the ubiquitin fragments would only 
complement and fold, allowing for cleavage of fusion constructs, when a 
dimerization signal brought them into close proximity. 
 Thus, as an alternative to CPS, we developed a new posttranslational, 
small molecule-mediated, technology for the manipulation of protein function.  
This system, termed SURF (Split-Ubiquitin for the Rescue of Function), places 
the complementation of ubiquitin under the control of the FKBP/rapamycin/FRB 
heterotrimerization system (Figure 3-1).  Before complementation a protein of 
interest is targeted for destruction by the proteasome through the introduction of 
an N-terminal degron.  Small molecule induced dimerization results in ubiquitin 
complementation and folding followed by cleavage of the protein of interest, 
thereby releasing it from the degron and rescuing its function. 
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Figure 3-1 : Overview of the SURF technology.  A protein of interest is 
genetically fused to a degron that destines the protein for destruction by 
the proteasome.  In between the protein under investigation and the 
degron are FRB and the C-terminal fragment of ubiquitin (UbC).  Upon 
addition of rapamycin a complex is formed between the small molecule 
and another engineered protein containing FKBP and the N-terminal 
ubiquitin fragment (UbN).  This complex creates a shunt away from 
degradation by allowing dimerization and complementation of the ubiquitin 
moiety through interactions between FKBP and FRB.  After ubiquitin 




Section 3.2 : Rescue of destabilized luciferase by ubiquitin hydrolysis 
 
For this strategy to be successful, we needed a degron that was powerful 
enough to keep the level of background activity low, but not so powerful that it 
would work faster than ubiquitin hydrolysis could rescue the target protein. Two 
general protein constructs were generated (Table 3-1, Figure 3-2). The first 
construct (1) contains maltose-binding protein (MBP) fused to the conditional 
complementation mutant of the N-terminal fragment of ubiquitin (I13A, residues 
1-37) followed by FKBP.  The second construct, bearing the protein of interest, 
has the following architecture: a degron, followed by FRB, the C-terminal 
fragment of ubiquitin (residues 35-76), and the protein under investigation.  
Initially we chose firefly luciferase as our model system, due to the ease and 
sensitivity of detection. We chose three degrons, which we theorized would have 
different degradation kinetics, to examine the gross requirements for protein 
rescue.  The first degron (2) is a fragment (residues 1-100) of the protein SopE 
from Salmonella typhimurium, which has been shown to reduce the cellular half-
life of proteins to which it is fused[58].  The two other degrons (3,4) are FRB 
mutants originally designed to allow the use of non-toxic derivatives of 
rapamycin. FRB* contains the three point mutations K2095P, T2098L, and 
W2101F and has already seen utility as a degron [30].  The other FRB derivative, 
which was used in the CPS work from the previous chapter, is a single point 
mutant (T2098L) and is here referred to simply as FRB.  Furthermore, we chose 
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to use three copies of these FRB derivatives to increase the avidity for the 
FKBP/rapamycin complex, thus driving complementation.  Additionally, the fusion 
of three copies of FRB to the C-luc fragment used in the previous chapter 
resulted in poor expression, suggesting that three copies of FRB may act as a 
degron. 
HeLa cells were transfected with the complementary pairs of the above 
constructs and treated with rapamycin (100 nM) or DMSO vehicle for 36 h.  
Cleavage from the degron and rescue of luciferase function were then measured 
by western blotting and luminescence activity, respectively (Figure 3-2).  When 
attached to the strong degron SopE (2), luciferase activity could not by rescued 
by the addition of rapamycin and no cleavage product was observed.  To ensure 
that 2 was being expressed, cells were treated with the proteasome inhibitor 
ZL3VS [95], and luciferase activity was indeed observed (Figure 3-3).  From this 
we concluded that the kinetics of degradation of SopE fusions must be faster 
than the kinetics of rapamycin induced complementation and/or ubiquitin 
cleavage.  Unlike the SopE fusion, detectable levels of constructs 3 and 4 were 
observed even in the absence of rapamycin (Figure 3-2).  Surprisingly, three 
copies of FRB resulted in a more robust degron than the corresponding FRB* 
construct, even though a previous study would suggest the opposite, at least for 
a single copy [30].  Upon addition of rapamycin, cleavage of luciferase from both 
constructs 3 and 4 was efficient, with 4 giving a better induction of activity.  
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Therefore, the general architecture of construct 4 was used as a blueprint for all 
subsequent SURF controlled proteins. 
 
Figure 3-2 : Evaluation of degrons. Constructs 1 and 2, 3, or 4 were 
transfected into HeLa cells and the ability of rapamycin to rescue 
luciferase activity was measured by western blotting (anti-HA) and 
luciferase activity.  All luciferase activity was normalized to an internal 





Table 3-1 : Architecture of SURF constructs 
 Construct   Sequence  
MBP-UbN-FKBP (1) MBP-EFEGGST-Ubiquitin (I13A, 1-37)-GGSTMAAA-
FKBP 






























Figure 3-3 : Rescue of SopE induced degradation with a proteasome 
inhibitor.  Cells were transfected with constructs 1 and 2 and treated with 
the proteasome inhibitor ZL3VS [95] for 6 h.  At this time expression of 2 
was measured by luciferase activity. 
 
To determine the kinetics of rescue, HeLa cells were transfected with 1 
and 4.  After 24 h, rapamycin (100 nM) or DMSO was added to the cells and 
luciferase activity and cleavage were measured at different time points (Figure 3-
4A).  Appearance and activity of luciferase were observable in as little as 2 h and 
grew until a plateau was reached after 24 h of treatment.  These kinetics are 
governed by the rate of protein synthesis in the cell and compare well with other 
degradation technologies [30, 32].  
 To explore the effects of varying rapamycin concentration, we transfected 
HeLa cells with our SURF constructs and treated them with different 
concentrations of rapamycin for 36 h (Figure 3-4B).  Both luciferase activity and 
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western blotting analysis confirmed that the amount of protein rescue could be 
altered by simply changing the rapamycin concentration.  The rapamycin 
mediated interaction of FRB and FKBP can also be reversed through the addition 
of another small molecule, ascomycin.  We treated HeLa cells expressing the 
SURF constructs with rapamycin (10 nM) and differing amounts of ascomycin 
(Figure 3-4C).  Western blotting analysis and luciferase assays clearly show that 
ascomycin is able to competitively reduce the levels of rescue.  Therefore, more 
precise control over levels of protein rescue can be achieved through the use of 
combinations of rapamycin and ascomycin concentrations.  Additionally, by 
washing away rapamycin and adding ascomycin the SURF system should be 
effectively turned off.  However, unlike other destabilized protein technologies 
where the protein of interest remains fused to the degron, the rate of 









Figure 3-4 : Characterization of the SURF system. (A) HeLa cells were 
transfected with constructs 1 and 4 and rapamycin was added.  Luciferase 
cleavage and activity was determined by western blotting (anti-HA) and 
luciferase activity at different time points.  (B) Cells were transfected and 
analyzed as in (A) to determine the effect of treatment with differing 
amounts of rapamycin.  (C) Cells were transfected and analyzed as in (A) 
to determine the effect of treatment with rapamycin and different amounts 
of ascomycin.  All luciferase activity was normalized to an internal renilla 
luciferase transfection control and performed in triplicate. 
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Section 3.3 : Application of SURF to other protein targets 
 
We next explored the generality of SURF by applying it to members of 
three important classes of proteins:  a protease, a kinase, and a transcription 
factor. 
Section 3.3.1 : SURF control of Caspase-3 
 
We chose caspase-3 as a candidate for SURF because, as a major 
executer of apoptosis, it is an important factor in cancer biology, with many types 
of cancer resistant to its effects [59, 96]. Although small molecule activators of 
apoptosis are available, a convenient method to titrate caspase-3 levels does not 
exist.  Therefore, SURF control of caspase-3 may help illuminate the roles of this 
protease. 
 Towards this end, we generated a SURF construct containing human 
procaspase-3 (5a), as well as a mutant thereof (5b) bearing a proline as the 
residue immediately following ubiquitin, thereby precluding ubiquitin hydrolysis 
(Table 3-1).  We hypothesized that 5b would be stabilized and avoid degradation 
utilizing a mechanism similar to previously described systems.  Constructs 1 and 
5a or 5b were then expressed in HeLa cells in the presence or absence of 
rapamycin (100 nM) and the rescue analyzed by western blotting (Figure 3-5A).  
Procaspase-3 was rescued with similar efficiencies in both the cleavage (5a) and 
stabilization (5b) constructs.  As a qualitative measure of the ability of these 
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inducible caspase-3 systems to actively partake in an apoptotic cascade, HeLa 
cells expressing these SURF constructs were treated with rapamycin (100 nM) 
for 24 h to allow adequate rescue.  At this time the cells were either treated with 
the apoptosis activator Staurosporine or the vehicle DMSO for 4 h and the extent 
of proteolysis, and procaspase processing, was interrogated (Figure 3-5B). 
Cleaved procapsase-3 was efficiently proteolyzed as judged by a significant 
decrease in the intensity of the procaspase-3 band.  Stabilization construct 5b 
was also processed upon staurosporine treatment; however, the level of 
proteolysis appears to be somewhat reduced when compared to cleavage 
construct 5a. 
 
Figure 3-5 : SURF can rescue the protease Caspase-3. HeLa cells 
were transfected with 1 and either a cleavage competent SURF construct 
5a or incompetent mutant 5b.  (A) The capacity for rapamycin rescue was 
then examined by western blotting (anti-HA).  (B) Processing of cleaved 
and stabilized caspase-3 during stauroporine induced apoptosis was 
analyzed by western blotting (anti-HA).  * indicates a background band. 
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Section 3.3.2 : SURF control of v-Src 
 
Rous Sarcoma virus Src (v-Src) is a constitutively active tyrosine kinase 
endowed with cellular transformative activity [97]. v-Src is a quintessential 
oncogene and the first tyrosine kinase discovered, and it’s cellular homologue (c-
Src) is involved in many cellular signaling pathways, many of which are still not 
fully understood [98].  Thus, we chose v-Src as a model protein to explore 
SURF’s utility for controlling kinase activities.  We generated a v-Src SURF 
construct and the corresponding stabilization mutant, 6a and 6b respectively 
(Table 3-1).  Constructs 1 and either 6a or 6b were coexpressed in SYF cells, 
which lack endogenous cellular Src kinase [99], and treated with rapamycin (100 
nM) or DMSO vehicle (Figure 3-6A).  In the presence of rapamycin both the 
cleaved and stabilized forms of v-Src were efficiently rescued from degradation.  
 The activity of these v-Src proteins against a wide array of substrates was 
then analyzed by a global anti-phosphotyrosine western blot (Figure 3-6B).  
Despite the near complete destruction of full-length 6a and 6b, two bands 
reacted strongly with the phosphotyrosine antibody in the absence of rapamycin.  
Furthermore, these bands were not present in mock-transfected cells.  The full-
length v-Src constructs (6a and 6b) could become self-phosphorylated and 
contribute to this signal.  However, because of the intensity of these bands, it 
seems likely that additional phosphorylated proteins are present and account for 
most of the signal. While the identities of these phospho-proteins are currently 
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unknown, we speculate that they may be members of the ubiquitin-proteasome 
pathway involved in the recognition and trafficking of our degron. Additional 
studies will be needed to test this idea.   
More important for the current study is that when treated with rapamycin, 
the cleavage construct showed rescue of v-Src function against a variety of 
cellular targets.  Furthermore, the pattern of phosphorylated proteins compares 
well to cells transfected with v-Src alone, albeit with much less intensity due to 
much larger amounts of v-Src in v-Src transfected cells (data not shown).  The 
stabilization construct 6b also showed rescue of v-Src activity.  However, 
interestingly this construct appears to phosphorylate a much smaller pool of 
substrates (compare lanes 2 and 4, Figure 3-6B).  Thus the activity of v-Src 
appended to the degron is distinct from the cleaved v-Src.   
To further determine the functional consequences of our v-Src constructs, 
we performed a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) cell proliferation assay [100].  SYF cells were transfected with 1 and 6a or 
6b, empty vector, or a plasmid containing v-Src.  After treatment with rapamycin 
(100nM) for 24 h, the cell proliferation rates were determined.  Rescue of v-Src 
from the cleavage construct 6a resulted in a similar proliferation rate as cells 
expressing v-Src alone (Figure 3-7).  In contrast, exposure of the stabilization 




Figure 3-6 : SURF can rescue the tyrosine kinase v-Src. SYF cells 
were tranfected with 1 and either the cleavage construct 6a or stabilization 
mutant 6b.  (A) Rescue of v-Src was explored by western blotting (anti-v-
Src).  (B) Recovered v-Src activity was examined by a global 
tyrosinephosphate western blotting (anti-pY).   Cells transfected with wild-
type v-Src express much higher levels of v-Src than SURF transfected 
constructs resulting in a very high level of cellular phosphorylation (‘v-Src’ 
lane).  A shorter exposure is shown on the far right for comparison to the 
SURF induced v-Src (1 + 6a). 
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Figure 3-7 : MTT cell proliferation assay. SYF cells were tranfected with 
1 and either the cleavage construct 6a or stabilization mutant 6b or the 
appropriate control plasmids.  The cells were then treated with Rapamycin 
or DMSO vehicle for 24h.  Cell proliferation was then quantified in triplicate 
by absorbance of reduced 3(4,5-dimethylthiazolyl-2)-2,5-
diphenyltetrazonlium bromide (MTT) at 570 nm. 
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Section 3.3.3 : SURF control of SMAD3 
 
Smad3 is a latent transcription factor involved in the transforming growth 
factor β (TGFβ) signaling pathway [101, 102].  In the basal state, Smad3 is 
unphosphorylated and primarily cytoplasmic.  Activation of the TGFβ receptor 
(which is composed of two receptor kinases TβR-I and TβR-II) results in 
phosphorylation of Smad3 on two serine residues at its extreme C-terminus.  
Phospho-Smad3 then accumulates in the nucleus where it forms heterotrimers 
with a related protein, Smad4, and regulates gene transcription.  Activated TGFβ 
receptors are also involved in Smad-independent signaling cascades[102].  Thus, 
stimulation of cells with TGFβ can lead to pleiotropic signaling effects making it 
difficult to understand the precise mechanistic basis of a phenotype.  Therefore, 
SURF control of Smad3 might provide a convenient tool to isolate the canonical 
TGFβ pathway from other receptor-mediated signaling cascades. 
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Figure 3-8 : Smad3E is a constitutive transcription factor. HeLa cells 
were pre-treated with the TβR inhibitor SB-43152 (10 µM) or DMSO 
vehicle for 16 h, and were subsequently transfected with a plasmid 
containing Smad3E or vector.  After 24 h, luciferase production from a 
3TP-luciferase plasmid was measured. All luciferase activity was 
normalized to an internal renilla luciferase transfection control and 
performed in triplicate. 
 
In preliminary studies, we generated a constitutively active version of 
Smad3 in which the two phospho-serine sites were replaced by glutamic acids.  
Based on structural studies [103], this double mutant was expected to mimic the 
acidic bis-phosphate surface in the active Smad3.  Indeed, this construct was 
shown to drive Smad-dependent transcription in cultured cells in a receptor-
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independent manner (Figure 3-8).  We then generated the SURF construct 7a 
and its stabilization proline mutant 7b (Table 3-1).  Treatment of HeLa cells 
expressing 1 and 7a or 7b with rapamycin (100 nM) resulted in escape from 
destruction for both the cleavage and stabilization constructs (Figure 3-9A).  
Rescue of the cleavage construct resulted in a ten-fold increase in transcriptional 
output, as measured by the production of a luciferase reporter driven by the 3TP-
binding element, when compared to cells treated with DMSO vehicle.  Isolation of 
Smad3E activity from endogenous Smads, by pre-treatment with SB43152 (10 
µM), an inhibitor of the TGFβ receptor kinase[104], resulted in a fifteen to twenty 
fold induction upon rapamycin treatment (Figure 3-10).  This increase is 
consistent with an almost complete recovery of Smad3E activity as compared to 
cells transfected with Smad3E alone as a positive control (Figure 3-9B).  In 
contrast to the cleavage construct, stabilization of the SURF proline mutant, 7b, 









Figure 3-9 : SURF can rescue SMAD3E activity. HeLa cells were 
transfected with 1 and either a cleavage competent SURF construct 7a or 
incompetent stabilization mutant 7b.  Rapamycin stimulated rescue was 
then examined by western blotting (A, anti-HA) and luciferase production 
(B) from a 3TP-luciferase-reporter plasmid.  All luciferase activity was 
normalized to an internal renilla luciferase transfection control and 




Figure 3-10 : Rescue of Smad3E in isolation from the TGFβ  receptor.  
HeLa cells were pre-treated with SB-43152 (10 µM) or DMSO vehicle for 
16 h, and were subsequently transfected with a plasmids 1 and 7a.  
Luciferase production from a 3TP-luciferase plasmid was measured after 
treatment with rapamycin (100 nM) or DMSO vehicle for 16 h. All 
luciferase activity was normalized to an internal renilla luciferase 
transfection control and performed in triplicate. 
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Section 3.4 : SURF alleles can reveal mechanistic details 
 
It has been known for almost two decades that TGFβ1 has the ability to 
activate its own translation and secretion [105].  In principle, SURF controlled 
Smad3 provides a window into the role of the canonical pathway in this feed 
forward mechanism since it should be possible to compare the kinetics of Smad-
dependent transcription with and without autocrine stimulation of the receptor. 
Accordingly, HeLa cells transfected with 1 and 7a were either left untreated or 
pre-treated with SB43152 (10 µM) for 16 h and then induced with rapamycin (100 
nM) or rapamycin (100 nM) and SB43152 (10 µM) respectively.  The extent of 
luciferase production from the Smad3 driven 3TP-luciferase reporter plasmid was 
then ascertained at different times (Figure 3-11A).   
In cells treated with the kinase inhibitor an almost linear increase in 
luciferase activity is seen throughout the entire time course.  Non-inhibited cells 
display the same linear increase at early time points, however, the rate of this 
increase is approximately double that of inhibited cells.  One possibility for this is 
that Smad3 activity may affect parallel signaling pathways, thereby increasing the 
signal resulting from TGFβ already present in the growth media.  Alternatively the 
difference may be an effect of treatment with rapamycin itself. It has been shown 
that FKBP12 binds the TGFβ type I receptors blocking their phosphorylation by 
TβR-II [106].  Rapamycin disrupts this interaction by blocking the binding surface 
on FKBP12 [107].  Both a TβR-I mutant defective in FKBP12 binding and 
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treatment of wild-type receptors with FKBP agonists generates modest increases 
in basal activity (see mock transfected cells Figure 3-9). 
In contrast to the early time points, cells that were not treated with the 
kinase inhibitor exhibited a dramatic increase in luciferase activity that 
commenced between 18 and 24 h.  This increase was not observed in cells 
treated with SB43152. We believe this is the result of increased secretion of 
TGFβ leading to autocrine receptor activation [104, 105], thereby revealing a role 
for Smad3 in the feed forward loop.  This data agrees well with the published 
kinetics of TGFβ induced expression of TGFβ mRNA (~6 h) and secreted TGFβ 
(~16 h) [105]. 
 
Figure 3-11 : Kinetic analysis of Smad3E transcriptional activation 
and rescue. HeLa cells were transfected with 1 and 7a and treated with 
rapamycin or a combination of rapamycin and SB43152. (A) Smad3E 
activity was determined by luciferase activity at different timepoints.  All 
luciferase activity was normalized to an internal renilla luciferase 
transfection control and performed in triplicate.  (B) Smad3E rescue was 
determined by Western blotting (anti-HA) at different time points. 
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To further characterize this time course, samples from each time point 
were analyzed by Western Blotting (Figure 3-11B).  In contrast to the build-up of 
luciferase (Figure 3-4) over the same timeframe, the amount of cleaved Smad3E 
decreased.  This phenomenon may contribute to the linear kinetics of the 
transcriptional luciferase reporter (Figure 3-11A) and could be the result of two 
possible scenarios.  The efficiency of Smad3E rescue could decrease at the later 
time points.  This scenario is unlikely, however, when taken in context with the 
luciferase-SURF data (Figure 3-4A) and that fresh media containing rapamycin 
was added every 6 h to avoid possible rapamycin metabolism.  Assuming that 
Smad3E rescue is constant at all time points, this decrease could be explained if 
Smad3E positively regulates its own destruction, perhaps by the ubiquitin-
proteasome pathway [108]. 
 
Section 3.5 : SURF in S2 cells 
  
Encouraged by the success of SURF in mammalian cells, we next 
attempted to use SURF to generate conditional alleles in S2 cells, with the 
intention of generating SURF controlled conditional alleles of DBT and SGG in 
Drosophila.  As mentioned in chapter 2, these proteins are required for 
developmental viability, so a conditional allele would allow the generation of adult 
nulls that could illuminate the genes’ roles in the maintainance of circadian 
rhythms. 
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 We first transferred our SURF allele of luciferase into a Drosophila 
expression vector (pAc5).  As expected, luciferase activity dramatically upon 
treatment with rapamycin (Figure 3-12).  However, we could not definitively state 
that this was the result of the rescue of protein stability as we could not detect the 
rescued protein by western blot.  However, based on the mammalian results, we 
concluded that rescue was functioning as intended and moved on to the 
generation of conditional alleles of DBT and SGG. 
 A SURF construct of DBT was generated and tested in S2 cells.  To our 
surprise, SURF-DBT was robustly expressed, even in the absence of rapamycin.  
Additionally, although some rapamycin induced cleavage could be seen, it was 







Figure 3-12 : SURF activation of luciferase in S2 cells.  Constructs 1 
and 4 were transferred to the pAc5 Drosophila expression vector.  S2 cells 
were transfected either with N-luc and C-luc (CPS, Figure 2-3B) or with 
Construct 1 and Construct 4 (SURF).  Cells were allowed to recover and 
express protein overnight and then were treated with rapamycin (100 nM) 
for 24 h.  Luciferase activity was measured using renilla luciferase as a 
transfection control.  Error bars represent standard deviation (n=3). 
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 We reasoned that, since the SURF-DBT construct was generated in pUAS 
and driven with heat shock induced GAL4, the failure to degrade SURF-DBT may 
be the result of an upregulation of chaperones such as HSP-70.  Thus, we 
instead expressed GAL4 under the control of the actin promoter.  Unfortunately, 
heat shock made no difference in the expression level of SURF-DBT, leading to 
the conclusion that the cells were unable to recognize SURF-DBT as 
destabilized.  Additionally, the failure to induce C-terminal ubiquitin cleavage 
suggests that either the ubiquitin hydrolases are unable to effectively recognize 




Figure 3-13 : A SURF allele of Doubletime.  S2 cells were transfected 
with a SURF-DBT construct and with Construct 1 either in the pAc5 vector 
in the the pUAS vector.  After overnight expression, indicated samples 
were incubated in a 37 °C water bath for 15 minutes.  All samples were 
then treated with rapamycin (R, 100 nM) or DMSO (D, 0.1%) for 24 h.  





Figure 3-14 : A SURF allele of SGG. S2 cells were transfected with a 
SURF-SGG construct and with Construct 1 in the pUAS vector along with 
Gal4 in the pAc5 vector.  After overnight expression, samples were treated 
with rapamycin (R, 100 nM) or DMSO (D, 0.1%) for 16 h.  SURF-SGG 
expression and cleavage was assayed by Western blotting (anti-HA). 
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 As in the case of our CPS-DBT alleles, we reasoned that perhaps the 
strange domain structure of DBT was responsible for the failure to generate a 
conditional allele.  As such, we turned instead to SGG.  A SURF-SGG construct 
was generated and tested.  As in the case of SURF-DBT, the SURF-SGG 
construct was robustly expressed even in the absence of rapamycin (Figure 3-
14).  However, unlike SURF-DBT, SURF-SGG displayed almost complete 
rapamycin induced cleavage. Thus, it appears that the failure of a SURF 
construct to be directed to the proteasome is unrelated to the ability of ubiquitin to 
complement and be cleaved. 
 Further examination of SGG reveals that it has much the same domain 
structure as DBT – a well conserved kinase domain followed by a unique and 
likely unstructured tail.  How this domain structure contributes to the difficulty in 
applying SURF (if indeed, that is the reason for the difficulty) remains a mystery 
though.  A reasonable possibility may be that the C-terminal domains of SGG 
and DBT are recruiting other proteins, forming a complex that may be stabilized 
against degradation.  In some cases, this complex may also interfere with protein 
complementation in trans – as in CPS-DBT and SURF-DBT. 
 Another possibility is simply that SURF is not general with respect to 
model systems.  The problem may not be the proteins but the S2 cells.  It is 
possible that FRB3 is more stable at 25 °C than at 37 °C.  It is also possible that 
ubiquitin complementation is not as efficient at 25 °C.  Although SURF-luc 
worked from an enzymatic activity standpoint in S2 cells, it was never formally 
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shown that this was due to stabilization of a destabilized luciferase.  However, 
given the experience with C-lucFRB3 (Figure 2-10), it seems likely that FRB3 is 
able to function as a degron in S2 cells.  Additionally, the rapamycin induced 
cleavage of SURF-SGG was highly efficient, showing that ubiquitin 
complementation is quite efficient at 25 °C.  Thus, it seems likely that SGG and 
DBT are the exceptions to SURF’s generality rather than the S2 cells.  To 
formally test this, however, more proteins that were successful in mammalian 
cells should be transferred to the S2 system.  If they behave similarly in S2 cells 
as they do in mammalian cells, one can conclude that the limits to SURF’s 
generality are at a protein level rather than at an organism level. 
 
Section 3.6 : Conclusions 
 
Section 3.6.1 : SURF can generate conditional alleles 
 
In summary, we have developed a new posttranslational technology for 
controlling protein function, SURF (Spilt Ubiquitin for the Rescue of Function).  
We were able to observe ubiquitin complementation and cleavage of protein 
fusions when the FRB* and FRB degrons were employed, but not with the strong 
SopE degron.  In contrast to SopE, both FRB* and FRB can be stabilized by 
interactions with rapamycin bound to FKBP. It is likely that this stabilized 
intermediate is essential, as it allows time for ubiquitin complementation and 
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hydrolysis of the protein fusion.  Luciferase was used as a model protein to 
examine the kinetics and tunability of SURF.  Like other degradation technologies 
[32, 109], the kinetics of SURF are limited to the rate of protein synthesis in the 
cell. SURF is highly responsive to the concentration of the small molecule 
activator rapamycin, and complementation and cleavage can be abrogated by 
the addition of another small molecule ascomycin.  SURF should therefore allow 
for highly tunable protein rescue by simple adjustment in rapamycin and 
ascomycin concentrations.  Unlike other degradation technologies, the protein of 
interest is released from the degron in SURF.  Therefore its native structure and 
stability is restored, which is attractive for the interrogation of protein function. 
 We used SURF to control the levels and activity of members of three 
important classes of protein:  a protease, a kinase, and a transcription factor.  
Rescue of caspase-3, a cysteine protease involved in apoptosis and important in 
many types of cancer, was observed and the cleaved native caspase-3 was 
apparently processed by upstream caspases during staurosporine-induced 
apoptosis.  The tyrosine kinase activity of v-Src was also efficiently recovered.  
SURF was also able to rescue Smad3E, effectively restoring all activity upon the 
addition of rapamycin.  In the midst of the complicated TGFβ signaling pathway, 
we were able to isolate Smad3 driven transcription by using two pharmacological 
agents, rapamycin and SB43152.  Kinetic evaluation of Smad3E regulated 
transcription allowed us to take a first step towards identifying it as a participant 
in a TFGβ feed forward loop.  Further analysis of this system with mutant TGFβ 
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receptors may allow us to define the effects of Smad3, as well as, rapamycin 
treatment on this important signaling pathway.   
In the case of the v-Src, Smad3E, and to a lesser extent caspase-3 
stabilization mutants, which rescued their proteins through stabilization and not 
cleavage, limited or altered activity was rescued even though protein levels did 
increase.  This highlights the complimentary utility of SURF to existing 
degradation technologies that require permanent fusion of degron domains to 
proteins of interest.  SURF represents an attractive alternative when the protein 
of interest is known to take part in protein-protein interactions or multimeric 
complexes as rescue is inextricably linked to generation of the native protein.  In 
the future this cleavage dependent rescue technology could be expanded to 
include other methods of protein regulation such as mislocalization or 
autoinhibition [84]. 
 
Section 3.6.2 : SURF vs. CPS 
 
 We turned to SURF as a means of generating conditional alleles since 
CPS proved to be difficult to apply to novel proteins.  In contrast, SURF controlled 
conditional alleles of novel proteins could be easily generated, at least in 
mammalian cells.  Unfortunately, an open question is whether the failure to 
generate conditional alleles of SGG and DBT was because of the proteins 
selected or the cells used.  Thus, although SURF appears to be more general 
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than CPS, there are limits, whether these turn out to be in terms of targetable 
proteins or in terms of accessible model organisms. 
 In its current incarnation, SURF is a considerably slower method of 
generating conditional alleles than CPS.  SURF, since it relies on protein 
synthesis to generate activity requires hours to function rather than minutes, as is 
the case for CPS.  If another N-terminal tag was used to inactivate the protein, 
such as one that mislocalizes the protein or one that directly inhibits the protein, 
much faster activation kinetics could potentially be obtained through SURF.  So, 
just as there is room to improve CPS as a means of generating conditional alleles 
through the use of libraries to screen for splicing junctions, there is room to 
improve SURF through changing the way in which activity is inhibited. 
 
Section 3.6.3 : The future of CPS and SURF 
 
 Conditional alleles generated by CPS are extraordinarily powerful.  They 
result in rapid, tunable and wild-type activity when successful but, as we found, 
generating and optimizing a conditional allele of a new target protein is neither 
straightforward nor guaranteed to be successful.  What is needed is an 
improvement in the generality of CPS.  This could take a number of forms.  The 
most straightforward would be a systematic variation of splicing sites, perhaps 
starting from our luciferase allele.  From this it may be possible to determine the 
rules or at least trends governing successful splicing sites.   
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 Alternatively, it may be possible to alter the intein itself to increase splicing 
promiscuity.  Work is already under way in the lab to evolve the naturally split 
Synechocystis dnaE intein to expand the range of allowed splice junctions.  The 
dnaE intein is not conditional, but  as a naturally split intein it is more stable and 
at least appears to be more promiscuous than the artificially split VMA intein that 
we used.  Thus, using a similar screen to that used by Liu et al. [36] it may be 
possible to develop a conditional dnaE intein, which would likely be a more 
general splicer than conditional VMA. 
Finally, as mentioned earlier, a means to generate and screen a library of 
splice sites would streamline the process of applying CPS to new protein targets.  
However, as it currently stands, application of CPS to new proteins is cripplingly 
time consuming and difficult.  Thus, any further work with CPS should be on 
improving the generality of the splicing rather than on immediately attempting to 
apply CPS to a new target. 
SURF, in contrast to CPS is a fairly general technique.  We have come 
across some exceptions to this, such as SGG and DBT, but these do appear to 
be just that – exceptions to an otherwise general technique.  Although SURF is 
not as fast as CPS in generating protein activity, it is still quite rapid.  Thus, given 
its generality, the generation of a new conditional allele should start with SURF.  
Only if temporal control on the timescale of minutes is required should CPS be 
attempted. 
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Chapter 4 : Regulation of the Bacterial Sigma Factor 
This work was performed in collaboration with Seth Darst of the 
Rockefeller University and Alex Shekhtman and David Cowburn of the New York 
Structural Biology Center.  This work is not related to the previous chapters but 
was nonetheless performed as part of my thesis work. 
 
Section 4.1 : Introduction 
 
The core bacterial RNA Polymerase (RNAP, subunit composition α2ββ’ω) 
is catalytically competent, but is unable to initiate promoter specific transcription 
[110-113].  Promoter specific transcription initiation requires the recruitment of a 
σ factor to form the RNAP holoenzyme [114, 115] (Figure 4-1).  The σ factor 
confers upon the RNAP holoenzyme the ability to recognize and bind promoter 
DNA and also aids in dsDNA melting to allow transcription initiation [38, 112, 113, 
116]. 
Bacterial species have anywhere from a single σ factor to over 60 which, 
together with various transcription factors regulate different transcriptional 
responses and programs [38, 112, 113].  σ factors fall into two broad classes, the 
σ-70 family and the σ-54 family [38].  The σ-70 family is more widespread, with 
multiple representatives in most bacterial species whereas some species do not 
even have a single member of the σ-54 family.  The σ-70 family is further 
subdivided into 4 groups.  The group 1 σ factors are responsible for the bulk of 
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transcription during log phase growth while group 2-4 σ factors or alternative σ 
factors fulfill more specialized functions such as stress responses [38]. 
 
 
Figure 4-1 : Prokaryotic transcription initiation.  In order to initiate 
promoter specific transcription initiation, the bacterial core RNAP (ααββ1ω) 
must form a holoenzyme complex with a σ factor.  The σ factor confers the 
ability to recognize and bind promoter DNA upon the RNAP holoenzyme. 
 
As DNA binding proteins, σ factors need to be regulated in order to 
prevent DNA binding at inappropriate times.  Unlike eukaryotes, prokaryotes 
cannot regulate their DNA binding proteins simply by excluding them from the 
nucleus, so alternative methods are needed.  The σ factors are regulated in two 
main ways (Figure 4-2).  Specialized or alternative σ factors are regulated 
through binding to anti-σ’s that prevent them from contacting DNA [38, 117, 118].  
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By contrast, the group 1 σ factors are self-regulatory in that they do not bind DNA 
prior to the formation of the RNAP holoenzyme [39, 40, 119].  
Group 1 σ factors are made of 4 conserved domains, known as σ-1.1, σ-2, 
σ-3 and σ-4 connected by flexible linkers.  A wealth of structural and biochemical 
information is available on σ-2, σ-3 and σ-4 [41-43, 117, 118, 120-123] but the 
structure of σ-1.1 has never been reported. σ-2 is involved in binding the –10 
element of the promoter as well as aiding in the melting of the double stranded 
DNA molecule [124].  σ-3 is also involved in recognizing the –10 element of the 
promoter, particularly in the extended –10 promoter [125]. σ−4 is responsible for 
recognizing and binding the –35 region of the promoter [126, 127].  All three 
domains are also responsible for forming contacts with the core enzyme.  The 
alternative σ factors contain σ-2, σ-4 and sometimes σ-3, but σ-1.1 is unique to 
the group 1 σ factors.  Although there is no structural information available on σ-
1.1, biochemical information shows that it plays a role in the transition from a 
closed to an open holoenzyme complex [128] and is responsible for preventing 








Figure 4-2 : Regulation of σ factors. σ factors are prevented from 
binding DNA at inappropriate times in two ways.  The alternative σ factors 
are bound by anti-σ factors to preclude DNA binding.  Group 1 σ factors, 
on the other hand, are regulated by an N-terminal domain known as region 
1.1 that is responsible for preventing DNA binding prior to the formation of 





Figure 4-3 : Region 1.1 prevents group 1 σ factors from binding 
promoter DNA.  5’-fluorescein labeled -35 promoter element DNA was 
incubated with σ-A (open circles) and with σ-A lacking region 1.1 (closed 
circles).  Protein-DNA binding was measured as a change in fluorescence 
polarization.  Modified from reference [119]. 
 
The mechanism by which region 1.1 prevents DNA binding by the group 1 
σ factors is still unknown. σ constructs lacking region 1.1 are able to bind 
promoter DNA while full length group 1 σ factors cannot [39, 40, 119] (Figure 4-
3).  Additionally, region 1.1 is able to interfere with DNA binding by region 4 in 
trans [40] (Figure 4-4).  This led to the proposal that region 1.1 binds to region 4 
to prevent DNA binding. 
 Camarero et al. investigated the possibility of a direct interaction between 
region 1.1 and region 4 through segmental isotopic labeling [119].  The last 50 
residues of region 4, known as region 4.2, form the binding surface for the -35 
promoter element.  Region 4.2 was segmentally labeled with 15N and 13C in 
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constructs containing and lacking region 1.1.  In this way, direct interactions 
between region 1.1 and region 4.2 would manifest themselves as differences in 
the NMR spectra of region 4.2 in the presence and absence of region 1.1.  
However, the spectra of the two constructs were largely similar (Figure 4-5), 
leading to the conclusion that there is no strong interaction between region 1.1 
and region 4.2.  As such, the authors proposed that region 1.1 was either binding 
N-terminal to region 4.2, inhibiting DNA binding through an allosteric mechanism 
or region 1.1 was not interacting with other domains of the σ factor and DNA 
binding was being prevented simply by electrostatic repulsion between the 
negatively charged region 1.1 and negatively charged DNA. 
We wished to determine the structure of σ-1.1 as well as the mechanism 
of autoinhibition of DNA binding.  A solution structure of σ-1.1 was determined by 
multidimensional NMR spectroscopy.  DNA binding autoinhibition was first 
investigated using a similar segmental labeling approach to the one taken by 
Camarero et al [119].  However, the spectra generated from the segmental 
labeled protein were not of sufficient quality to make residue assignments.  The 
only conclusion that could be drawn is that region 1.1 was likely making some 
contacts with other portions of the protein.  Instead, an intramolecular 
crosslinking approach was taken which revealed that multiple interdomain 
contacts are made between a negative face of region 1.1 and the DNA binding 




Figure 4-4 : DNA binding inhibition by region 1.1 in trans.  End-
labeled ptac promoter DNA was incubated with σ-70 constructs containing 
the indicated residues (“Binder”) as well as σ-70 region 1.1 (“Inhibitor”).  
Protein-DNA complexes were captured on nitrocellulose filters.  DNA-
binding inhibition by region 1.1 was measured as a decrease in the 











Figure 4-5 : Segmental labeling of region 4.2. (A-C) 1H[15N] HSQC-
TROSY spectra of region 4.2 in isolation (A), in a σ-A construct lacking 
region 1.1 (B) and in full length σ-A (C). (D-F) 1H[13C] HSQC-TROSY 
spectra of of region 4.2 in isolation (D), in a σ-A construct lacking region 
1.1 (E) and in full length σ-A (F).  The presence (C, F) or absence (B, E) of 
region 1.1 does not appear to affect the spectra of region 4.2 significantly.  




Section 4.2 : Results 
Section 4.2.1 : Determination of the structure of Region 1.1 
 
 We chose to work on the T. maritima σ-A protein rather than the E. coli σ-
70 protein.  T. maritima σ-A region 1.1 is well conserved in comparison to  E. coli 
σ-70 (Figure 4-6A).  In fact, T. maritima σ-A is homologous enough to E. coli σ-
70 to be capable of forming a functional holoenzyme complex with E. Coli RNAP 
(Figure 4-6B).  Thus, since T. maritima σ-A is functionally similar if not identical 
to E. coli σ-70 but is both considerably smaller (46.5 kDa vs. 70 kDa) and is 
thermostable, we reasoned it would be a good choice for our structural studies. 
A list of constructs used in the structure determination and segmental 
labeling work is shown in Table 4-1.  Preliminary work revealed that the first 25-
30 residues of T. maritima σ-A are unstructured, as are residues ~95-116.  These 
unstructured regions made determination of a structure difficult.  Unfortunately, 
although the first 25-30 residues are unstructured, they are required for 
expression.  As such, the construct we used for structure determination encoded 
residues 1-95 with mutations to install a thrombin protease site to remove the 
unstructured N-terminal region (Figure 4-7).  This construct expressed well and 
could be efficiently processed to generate the desired construct (Figure 4-8).  






Figure 4-6 : T. maritima σ-A is similar to E. coli σ-70.  (A) An alignment 
of E. coli σ-70 and T. maritima σ-A region 1.1.  Identical residues are 
indicated by ‘*’, similar residues are indicated by ‘:’ and dissimilar residues 
are indicated by ‘.’.  (25% identity, 58% similarity) (B) Abortive 
transcription initiation reactions on a T7A1 promoter in the presence of E. 
coli RNAP core and the indicated σ factor.  Reaction products (CpA32pU 
trinucleotide) were resolved by denaturing SDS-PAGE and analyzed by 
autoradiography. 
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Table 4 – 1 : Constructs used for NMR analysis of σ-A 
Name Sequence* Notes 
σ-A(29-95) gshm-(29-95)-g N-terminal unstructured region removed by thrombin cleavage 
σ-A(1-95) 1-95-g  
σ-A(29-115) gshm-(29-115)-g N-terminal unstructured region removed by thrombin cleavage 
σ-A(117-399) c-(118-399) Regions 2-4 
σ-A(117-318) c-(118-318) Regions 2-3 
σ-A(EPL) gshm-(29-399) S116G, S117C 
Generated by ligation of σ(29-115) and 
σ(117-399).   
σ-A(Δ4) gshm-(29-318) S116G, S117C 
Generated by ligation of σ(29-115) and 
σ(117-318). 
σ-A(97-399) c-(98-399)  
σ-A(EPL2) 1-399 S96G,S97C 
Generated by ligation of σ(1-95) and 
σ(97-318). 
*Numbers refer to T. maritima σ-A residue numbers 
 
 
Figure 4-7 : Design of the σ-A(29-95) construct used for structure 
determination.  Preliminary results revealed that the N- and C-termini of 
σ-1.1 were unstructured (top, highlighted in gray) but that the N-terminus 
was required for expression.  A new construct was generated encoding 
residues 1-95 (middle).  A thrombin protease recognition site (middle, 
highlighted in yellow) was incorporated by PCR mutagenesis for the 
removal of the unstructured N-terminus.  The final, thrombin processed 
construct used for structure determination contained residues 29-95 




Figure 4-8 : Expression of σ-A(29-95). (A) ESI-MS of unlabeled σ-A(29-
95) demonstrates the correct construct is expressed.  (B) (left) ESI-MS of 
15N, 13C labeled σ-A(29-95) shows that approximately 450 spin labels are 
incorporated.  (right) SDS-PAGE of the NMR sample used to generate the 
spectrum shown in Figure 4-9.  The amino acid sequence of the construct 




Figure 4-9 : 1H[15N] HSQC spectrum of σ-A(29-95). 1H[15N] spectrum of 
15N, 13C labeled σ-A(29-95) at 298 K (protein concentration 370 µM in 10 
mM NaPi pH 6.5, 100 mM NaCl, 1mM EDTA).  The amino acid sequence 
of the construct is shown at the top of the figure. 
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 Uniformly 15N and 13C labeled σ-A(29-95) was used to obtain the main- 
and side-chain assignments of the 1H, 15N, and 13C resonances using the 
standard set of triple-resonance 3D experiments [129].  An initial assessment of 
the σ-1.1 secondary structure was made using the deviations of assigned 
chemical shifts from random coil [130].  This indicated that the domain contains 
three α helices.  The solution structure of region 1.1 was solved using restraints 
generated from standard multi-dimensional NMR experiments by Alex 
Shekhtman, Kaushik Dutta and David Cowburn (NYSBC).  Briefly, structure 
calculations were performed using 27 hydrogen bond restraints inferred from 
slow H/D exchange, 105 dihedral (φ and ψ) angle restraints and 919 distance 
constraints from aromatic, aliphatic and amide NOEs.  The 20 lowest energy 
structures (Figure 4-10) have an average pairwise root-mean-square deviation 











Figure 4-10 : The 20 lowest energy structures of region 1.1.  Shown is 
a superimposition of the backbone of the 20 lowest energy structures of 
region 1.1 that were obtained from 3D NMR based structural restraints.  
Each structure is individually colored.  The N-termini are in the upper right 
and the C-termini are in the bottom half of the figure.  Images generated 
using MacPYMOL (Delano Scientific). 
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Figure 4-10 : The 20 lowest energy structures of σ-1.1.   
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 Region 1.1 contains three helices (Figure 4-11) and has limited homology 
to any structure in the protein data bank (DALI search, [131]).  Helix 1 (H1) is the 
longest helix and contains residues Q30-K45.  H1 is connected by a four residue 
linker to the smallest helix (H2) comprising residues Y50-A56.  H2 is connected 
by a 9 residue loop to the final helix (H3) which stretches from N67-K78.  H2 and 
H3 are roughly anti-parallel to one another and pack perpendicularly against H1.  
A hydrophobic core is formed by residues from all three helices and part of the C-
terminal tail (Figure 4-12).  H1 contributes I35, L38, and I39.  H2 contributes 
Y50, I53 and A56. H3 contributes L68 and I72.  I69 and L76 appear to be partially 
buried as well.  Finally, the side-chains of I81 and I83, from the C-terminal tail of 
σ-1.1 project directly into the hydrophobic core. 
The relatively small structured portion of the region, less than 70 residues, 
may explain the difficulty in obtaining a crystal structure of region 1.1.  The N- 
and C-terminal unstructured regions likely interfere with crystal packing.  
Additionally, the C-terminal unstructured region probably forms a flexible linker to 
σ-2.  In the crystal structure that included region 1.1 but could not resolve it [43], 
region 1.1 was likely mobile in the crystals, resulting in a diffuse electron density 






Figure 4-11 : Solution structure of region 1.1.  Shown here is a cartoon 
representation of the secondary structure elements of σ-1.1.  The structure 
is rainbow spectrum colored from N-terminus (blue) to C-terminus (red).  
Images were generated using MacPYMOL (Delano Scientific). The amino 
acid sequence of the construct is shown at the top of the figure with 




Figure 4-12 : The hydrophobic core of region 1.1.  Shown is a cartoon 
representation of region 1.1.  Residues that form the hydrophobic core are 
shown in red with line representations of the side-chains.  Images 
generated using MacPYMOL (Delano Scientific). 
 
 It has been shown that I53 of σ-70 plays an important role in the function 
of region 1.1 as an I53A mutation is defective in promoter DNA binding by the 
RNAP holoenzyme [132].  The authors of the study propose that the defect is due 
to difficulty in displacing σ-1.1 from the DNA binding region of the RNA 
polymerase holoenzyme.  Examining the structure of region 1.1, I53 (I81 in T. 
maritima) is located immediately after H3, with its sidechain projecting into and 
forming a portion of the hydrophobic core (Figure 4-13).  Thus, it is likely that the 
I53A mutation weakens a hydrophobic interaction between the C-terminal tail of 
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region 1.1 and the helical core.  This is consistent with the fact that I53V and 
I53F mutations in σ-70 behave roughly as wild-type [132].  The disruption in the 
fold of region 1.1 caused by the I53A mutation likely interferes with the 
conformational changes required in the σ factor to allow DNA binding by the 
RNAP holoenzyme. 
The electrostatic surface of region 1.1 is mostly negative, as expected 
from the amino acid composition (Figure 4-14).  However, strikingly, H1 of the 
structure is neutral if not slightly positive, resulting in a slightly positive patch on 
an otherwise strongly negative surface.  The possible functional importance of 





Figure 4-13 : The I53A mutant explained structurally.  I53 (I81 in T. 
maritima) is required for efficient binding of RNAP holoenzyme to promoter 
DNA.  Mutation to alanine disrupts RNAP : DNA binding.  The side chain 
of I81 (spheres) projects into the hydrophobic core of σ-1.1, suggesting 
that the I53A deficiency is due to disruption of the σ-1.1 fold. Images  were 
generated using MacPYMOL (Delano Scientific). The amino acid 
sequence of the construct is shown at the top of the figure with secondary 






Figure 4-14 : Surface charge of region 1.1.  Most of surface of region 
1.1 is negatively charged (red), but the surface of helix 1 is neutral (white) 
with some positively charged (blue) patches.  Structure is shown in a 
similar orientation to that in Figure 4-11.  Images generated using the 
GRASP program [133]. 
 
Section 4.2.2 : Segmental labeling of T. maritima σ-A 
 
 In order to determine the mechanism by which region 1.1 inhibits DNA 
binding, we decided to use Expressed Protein Ligation (EPL) to make full length 
and truncated σ factors in which only region 1.1 was labeled with 15N and 13C.  By 
comparing the NMR spectra from these samples to that of free region 1.1, we 
would be able to determine what, if any, part of σ interacts with region 1.1 as well 
as which residues of region 1.1are involved. 
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 Some mechanisms by which region 1.1 could interfere with DNA binding 
are shown in Figure 4-15.  Since region 1.1 is very negatively charged 
(calculated pI = 4.52) it is possible that region 1.1 prevents DNA binding by 
simple electrostatic repulsion (Figure 4-15A).  This would require no interactions 
between region 1.1 and the rest of the protein.  As such, the spectra of region 1.1 
in isolation would be expected to be nearly identical to region 1.1 in both full 
length σ-A (σ-A(EPL)) and in σ-A lacking region 4 σ-A(Δ4)) (Figure 4-16).  Such 
a model would be consistent with NMR data from an earlier study in which no 
strong interaction between region 1.1 and region 4.2 could be detected [119].  If 
region 1.1 acts by binding to region 4 (Figure 4-15B), then the spectra of region 
1.1 should be very similar in isolation and in σ-A(Δ4).  However, the spectra 
should be different in σ-A(EPL), reflecting the perturbations caused by contact 
between region 1.1 and region 4.  An interaction between region 1.1 and region 4 
is predicted by region 4 DNA binding inhibition in trans by region 1.1 [40].  If 
region 1.1 is binding N-terminal to region 4 (Figure 4-15C), then the spectra of σ-
A(EPL) and σ-A(Δ4) would be similar to one another, but different from region 1.1 
on its own.  In this case, further truncations or deletions could be made to 
determine the exact region of binding. The three models are not mutually 














Figure 4-15 : Possible mechanisms by which region 1.1 could 
autoinhibit DNA binding.  (A) The negative charge of region 1.1 could 
repel negatively charged DNA.  (B) Region 1.1 could bind to region 4 and 
directly prevent DNA binding.  (C) Region 1.1 could bind N-terminal to 




Figure 4-15 : Possible mechanisms by which region 1.1 could 




Figure 4-16 : Predicted NMR spectra of isotopic labeled region 1.1 if 
region 1.1 acts by direct binding to region 4.  If σ-1.1 is directly binding 
to σ-4 (Figure 4-14B), then the spectrum of σ-1.1 in isolation (top) should 
be similar to the spectrum of σ-1.1 in σ-A lacking σ-4 (middle).  However, 
interaction between σ-1.1 and σ-4 should be apparent in the spectrum of 
full length σ-A (bottom) as perturbations in the residues involved (filled 
circles).   
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 Segmental isotopic labeling of σ-A was achieved through EPL between 
region 1.1 constructs containing C-terminal thioesters and σ-2-σ-4 constructs 
containing N-terminal cysteines (Figure 4-17).  Isotopically labelled σ-1.1 was 
obtained by expression of a (σ-1.1)-(intein)-(chitin binding domain) fusion in 
minimal media made in D2O and containing only 15N and 13C as nitrogen and 
carbon sources.   The σ-1.1 thioester was generated by on column intein thiolysis 
(see Methods).  C-terminal constructs were expressed in LB media.  N-terminal 
cysteine was exposed by proteolytic processing with Factor Xa. 
The segmental labeling work was initiated before it was determined that 
residues 95-115 of region 1.1 were unstructured, so a region 1.1 construct 
containing residues 1-116 (S116G as an artifact of cloning) that had a thrombin 
site to remove the unstructured N-terminal portion was used (Figure 4-18).  The 
final processed construct contained residues 29-116 (S116G).  We initially 
wished to make two segmental labeled constructs : full length σ-A (σ-A(EPL)) 
and a C-terminally truncated construct lacking region 4 (σ-A(Δ4)).  We reasoned 
that with these two constructs we could determine if there were any contacts 
between σ-1.1 and σ-4 (Figure 4-16).  The C-terminal constructs we used 
contained residues 117(S117C)-399 for the generation of σ-A(EPL) and residues 












Figure 4-17 : Semi-synthetic scheme used to generate segmental 
labeled σ-A.  σ-A(29-115) was expressed in labeled (2H, 15N, 13C) media 
as a fusion with the GyrA intein and a chitin binding domain affinity tag 
(top left).  The sample was purified by immobilization on a chitin column 
and the unstructured N-terminal tail by thrombin proteolysis. σ-A(29-115) 
thioester was released by thiolysis.  C-terminal constructs (σ-A(117-399) 
or σ-A(117-318)) were expressed with an N-terminal hexahistidine 
purification tag followed by a Factor Xa recognition site (IEGR).  Following 
purification of the C-terminal constructs, the purification tag was removed 
by Factor Xa proteolysis, exposing an N-terminal cysteine. σ-A(EPL) or σ-
A(Δ4) were generated by the native chemical ligation reaction between the 












Figure 4-18 : σ-A(29-115) construct used in segmental labeling 
studies. The construct used for segmental labeling encoded residues 1-
115 (top).  A thrombin protease recognition site (top, highlighted in yellow) 
was incorporated by PCR mutagenesis for the removal of the unstructured 
N-terminus.  The final, thrombin processed construct used for structure 
determination contained residues 29-115 (bottom) with short N- and C-
terminal tails that were artifacts of cloning (bottom, lower-case). 
 
 The 2H, 13C, 15N labeled region 1.1 thioester was generated with minimal 
difficulty and could be isolated in multimilligram amounts after chromatography 
purification (see methods).  The C-terminal constructs were more difficult to 
express and purify.  Despite extensive efforts, neither σ-A(117-399) nor σ-A(117-
318) could be characterized by mass spectrometry, presumably due to poor 
ionization properties, so it was never clear what percentage of the N-terminal 
cysteine was exposed by Factor Xa cleavage.  It was also determined that 
storage in glycerol, which contains glyceraldehyde contaminants was likely 
capping much of the N-terminal cysteines that were exposed (J. P. Pellois, 
unpublished data), so the protein had to be prepped immediately prior to ligation. 
σ-A(117-399) had the additional complication of poor solubility.  Solubility was 
improved through the use of the detergent CHAPSO, but added new difficulties.  
The expense of CHAPSO prohibited buffer exchange by dialysis, necessitating 
 141 
buffer exchange using a centrifugation concentration device.  Not only was this 
process slow, but because it involved repeatedly concentrating the protein, it led 
to sample loss from precipitation.   Additionally, as CHAPSO needed to be used 
at or near the CMC, sometimes the concentration of CHAPSO also rose to levels 
at which it interfered with gel or HPLC analysis as well as with the NMR spectra. 
 Also problematic was the purification of the ligation products.  The 
reactions did not go to completion (Figure 4-19) so both reactants needed to be 
separated from the ligation product.  Region 1.1 is strongly negatively charged 
(calculated pI = 4.52), the C-terminal fragments are strongly positively charged 
(σ-A(117-399) calculated pI = 9.39, σ-A(117-399) calculated pI = 9.28) and the 
ligation products weakly negative (σ-FL calculated pI = 6.52, σ-Δ4 pI = 5.45).  We 
reasoned that these charge differences could be exploited using ion exchange 
chromatography to purify the ligation products.  This was reasonably successful 
for σ-Δ4 reaction mixtures.  Unfortunately, a portion of both region 1.1 and σ-
A(117-399) co-eluted with σ-FL on ion exchange so only a small amount of the σ-
FL containing fractions could be isolated.  We interpret the co-migration of σ-FL, 
σ-1.1 and σ-A(117-399) as indicative of the formation of a complex between σ-
A(117-399) and σ-1.1.  This is possibly the trans-inhibited complex observed by 
Dombroski and Gross [40]. 
 Despite these difficulties, σ-A(Δ4) and σ-A(EPL) were made, albeit in low 
quantities and of moderate purity (Figure 4-19).  NMR spectra from both σ-A(Δ4) 
and σ-A(EPL) were obtained, but were of poor quality and could not be fully 
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interpreted.  In fact, σ-A(EPL) was found to have degraded slightly over the 
course of the NMR experiment (Figure 4-20).  The only thing that was clear in 
the segmentally labeled spectra is that in both σ-A(Δ4) and σ-A(EPL), the 
fingerprint region in the 1H[15N] HSQC of region 1.1 is perturbed relative to 
isolated region 1.1 (Figure 4-21).  The spectra differ both in chemical shifts of the 
resonances, which suggests a change in a residues local environment and in 
broadening of peaks which suggests exchange processes on the NMR timescale 
that could indicate transient interactions. Thus, there are likely contacts between 
region 1.1 and other portions of the protein although, due to the quality of the 
spectra, it could not be determined which residues of region 1.1 were interacting 
and what they were interacting with. 
 The only major difference between the wild-type σ-A and the σ-A(EPL) 
construct is that σ-A(EPL) lacks the first 28 residues.  These residues are 
unstructured and were removed out of a desire for a simplified NMR spectra.  
However, these residues might be required for protein stability and solubility.  
Earlier attempts to express region 1.1 without the N-terminal residues were 












Figure 4-19 : Segmental labeling of σ-A(Δ4) and σ-A(EPL).  (A) σ-
A(EPL) (residues 29-399) and σ-A(Δ4) (residues 29-318) can be 
generated by EPL although the reaction is slow (1 week at room 
temperature) and inefficient.  (B) Purified NMR samples used to generate 
the spectra shown in Figure 4-21.  Protein samples were resolved by 








Figure 4-20 : Degradation of segmental labeled σ-A(EPL).  NMR 
samples from Figure 4-19 were analyzed before and after NMR spectra 
were acquired.  In the case of σ-A(EPL), degradation products (marked by 
*) increased over the course of the experiment. Protein samples were 





Figure 4-21 : 1H[15N] HSQC spectra of σ-A(29-115) in σ-A(EPL) and σ-
A(Δ4).  (A) 1H[15N] HSQC spectrum of region 1.1 (residues 29-115) in 
isolation.  (B) 1H[15N] HSQC-TROSY spectrum of region 1.1 in σ-A(Δ4) 
(residues 29-318).  (C) 1H[15N] HSQC-TROSY spectrum of region 1.1 in σ-
A(EPL) (residues 29-399).  All spectra were acquired at 298 K. 
 
 When the structure of region 1.1 was determined it was also found that 
residues from ~95-116 were also unstructured.  We reasoned that by only 
labeling residues 1-95, we would be able to obtain spectra that were simple 
enough to interpret.  By retaining residues 1-28, we hoped to obtain a stable, 
soluble protein.  We decided to perform the ligation between residues 96 and 97.  
In this way, all of the structured residues would be labeled.  Additionally, we 
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reasoned the S97C mutation that would be required for ligation was conservative 
enough to be unlikely to affect the σ function significantly. 
To ensure that the spectra would be interpretable in the full length, ligated 
construct, we first generated 15N, 13C labeled σ-A(1-95) (Figure 4-22).  The 
spectrum obtained was well dispersed, with sharp peaks, suggesting that 
meaningful conclusions could be drawn from the spectra in the full length protein 
(Figure 4-23).  The full length protein could be obtained by EPL (Figure 4-24A) 
and behaved as wild type in abortive initiation assays (Figure 4-24B).  However, 
the yield of the ligation reaction was low, and only small amounts of protein could 
be isolated after purification (data not shown). It is possible that with further 
optimization of the expression and purification of the protein building blocks, the 
ligation reaction conditions and especially the purification of the reaction 
products, we would have been able to generate an NMR sample of sufficient 
quality.  However, the experience with ligation between residues 116 and 117 
suggested that this optimization would be time consuming and difficult.  
Consequently, we decided to take a different approach involving crosslinking to 
probe potential intramolecular interactions. 
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Figure 4-22 : Expression of σ-A(1-95). (A) ESI-MS of unlabeled σ-A(1-
95) demonstrates the correct construct is expressed.  (B) (left) ESI-MS of 
15N, 13C labeled σ-A(1-95) shows that approximately 750 spin labels are 
incorporated.  (right) SDS-PAGE of the NMR sample used to generate the 
spectrum shown in Figure 4-23. The amino acid sequence of the 





Figure 4-23 : 1H[15N] HSQC spectrum of σ-A(1-95). 1H[15N] spectrum of 
15N, 13C labeled σ-A(1-95) at 298 K (protein concentration 300 µM in 10 
mM NaPi pH 6.5, 100 mM NaCl, 1mM EDTA).  The amino acid sequence 
of the construct is shown at the top of the figure. 
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Figure 4-24 : Semi-synthesis of σ-A(EPL2).  (A) σ-A(EPL2) can be 
generated by ligation of σ-A(1-95) thioester and σ-A(97-399) containing N-
terminal cysteine although, as in the case of ligation at residue 116 the 
reaction is slow and inefficient. Protein samples were resolved by SDS-
PAGE (15% acrylamide) and visualized by coomassie stain. (B) Purified 
σ-A(EPL2) behaves as wild type (σ-A) in abortive transcription initiation 
reactions on a T7A1 promoter in the presence of E. coli RNAP core and 
the indicated σ factor.  Reaction products (CpA32pU trinucleotide) were 
resolved by denaturing SDS-PAGE and analyzed by autoradiography. 
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Section 4.2.3 : Probing autoinhibition by crosslinking 
 
 Since we were unable to characterize interdomain interactions with region 
1.1 by NMR, we chose instead to investigate possible intramolecular interactions 
using a crosslinking strategy.  The strategy we used is shown schematically in 
Figure 4-25 and the crosslinker used is shown in Figure 4-26.  We reasoned 
that transfer of a biotin tagged crosslinker from region 1.1 to another domain 
would indicate an interdomain interaction. 
 
Figure 4-25 : Crosslinking strategy for detecting interdomain 
interactions.   A tagged crosslinker (red star) is attached by disulfide 
exchange to a surface cysteine.  Following crosslinking and digestion, the 
disulfide is reduced, transferring the tag to regions in close proximity to 




Figure 4-26 : Synthesis of crosslinker.   A novel crosslinker was 
synthesized for use in these studies by Matthew Pratt (The Rockefeller 
University). (A) pentafluorophenyl trifluoroacetate, pyridine, DMF, 45 min, 
85%; (B) diisopropylethylamine, DMF, 16 h, 83%; (C) trifluoroacetic acid, 
H2O, 1h, 94%; (D) pentafluorophenyl trifluoroacetate, pyridine, DMF, 45 
min, 80%; (E) diisopropylethylamine, DMF, 16 h, 74%.  Three functional 
moieties were incorporated.  A fluorophenylazide was included for 
crosslinking, an exchangeable disulfide was included for attachment to a 
surface cysteine and a biotin served as both an affinity tag for enrichment 
of crosslinked samples and as a marker for Western blotting. 
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 Using the structure of region 1.1, we selected ten surface residues to 
mutate to cysteine for crosslinker attachment (Figure 4-27, Table 4-2).  These 
were designed to give broad coverage of the surface of region 1.1.  Since T. 
maritima σ-A contains no native cysteine, no additional mutations needed to be 
made.  Each construct thus contained only a single cysteine, allowing site 
specific attachment of the crosslinker. 
 



















































































Figure 4-27 : Sites of crosslinker attachment.  Surface rendering of 
region 1.1 shown in the same orientation as Figure 4-11.  Shown in red 
are the residues that were mutated to cysteine for attachment of the 
crosslinker. T26 was mutated to serine in the construct used for structure 
determination and is thus indicated in the figure as “s(T)26”.  Images were 
generated using MacPYMOL (Delano Scientific). The amino acid 
sequence of the construct is shown at the top of the figure with residues 
that were mutated to cysteine in red, and those that were left unchanged 
in blue. 
 
 Of the ten point mutations made, eight could be expressed and purified 
(Figure 4-28). The failure to obtain two of the mutants is mysterious.  DNA 
sequencing confirmed that the cloning was correct.  The E51C construct appears 
to express in very low quantities and behaves strangely (Figure 4-28).  The SDS-
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PAGE mobility of E51C differs from the other mutants and from wild type.  
Additionally, a mass of the purified protein could not be obtained.  No evidence of 
expression could be detected for the E77C protein (data not shown). 
 
Figure 4-28 : Purification of σ-A cysteine mutants. The indicated 
purified σ-A cysteine mutants were resolved by SDS-PAGE (4-12% 
Acrylamide) and visualized by coomassie stain.  When obtained, masses 
of the constructs are reported in Table 4-2. 
 
 The 8 mutants that were successfully generated could be labeled with the 
crosslinker 4.5 using a disulfide exchange process (Figure 4-29).  In all cases, 
the crosslinker could be removed by reduction with DTT.  However, after the 
labeled proteins were irradiated with a laser at 325 nm, the crosslinker could no 
longer be removed with DTT, suggesting that crosslinking to the protein had 
occurred.  Labeled σ factors behaved as wild type in abortive trancription initation 
assays (4-30A).  The presence of the label did not interfere with DNA binding 












Figure 4-29 : Crosslinker 4.5 can be attached through a disulfide.  (A) 
Indicated σ-A mutants were labeled with crosslinker by disulfide exchange.  
Samples were then treated with laser light at 325 nm and reduced with 
DTT.  (B) Samples were then resolved by SDS-PAGE and analyzed by 
Western blot (Streptavidin-HRP).  DTT reduction removed the crosslinker 
(UV “–“ samples) indicating that the attachment was through a disulfide 










Figure 4-30 : Attachment of crosslinker does not affect σ-A function.  
Wild type σ-A and σ-A cysteine mutants were labeled with crosslinker and 
tested for function.  (A) Three examples of abortive transcription initiation 
on a T7A1 promoter in the presence of E. coli RNAP core and the 
indicated σ factor.  Reaction products (CpA32pU trinucleotide) were 
resolved by denaturing SDS-PAGE and analyzed by autoradiography.  σ-
70 was provided by Andrey Feklistov (Darst lab).  It is believed that the low 
overall level of σ-A activity in these particular assays is because the 
protein used was frozen and not due to the incorporation of crosslinker 
since wild type σ-A (which does not bind crosslinker) displays similarly low 
activity.  (B) DNA binding of σ-A constructs measured by gel shift.  5’-
fluorescein labeled -35 promoter element DNA (5 µM) was incubated with 
the indicated σ-A (10 µM) then resolved on a 1% agarose gel and imaged 
by fluorescence.  Protein:DNA binding was indicated as a shift in gel 
mobility (indicated by arrow).  As expected, only σ-A that lacks region 1.1 







Figure 4-30 : Attachment of crosslinker does not affect σ-A function.   
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Having established that we could form crosslinks from region 1.1, we next 
set about determining what portions of the σ factor region 1.1 was contacting.  
We made numerous attempts to directly identify a crosslinked fragment by mass 
spectrometry.  Crosslinked proteins were reduced with DTT or TCEP treatment 
and treated with iodoacetamide to cap the cysteine side chain.  Samples were 
then resolved by SDS-PAGE.  Silver stained bands were then digested by in gel 
trypsinolysis, extracted and analyzed by MALDI-TOF mass spectrometry.  In no 
case could the unambiguous identification of a crosslinked peptide be made.  
Additionally, crosslinked samples were digested with trypsin in solution and 
analyzed by LS-MSMS and, once again, no crosslinked peptide could be 
identified. 
 We then turned to gel based methods to map the sites of crosslinking.  We 
decided to use a cyanogen bromide (CNBr) digestion of crosslinked samples to 
identify interdomain crosslinks.  CNBr cleaves after methionine residues, of which 
there are 13 in σ-A.  The predicted CNBr digestion pattern is shown in Figure 4-
31.  The majority of crosslinking is predicted to occur locally, to nearby portions of 
region 1.1.  Fortunately, region 1.1 is entirely contained within a single CNBr 
fragment that is more than twice as large as the next largest.  Thus, region 1.1 
can be easily resolved from region 2-4 CNBr fragments by SDS-PAGE, allowing 
one to distinguish between local and inter-domain crosslinking. 
 160 
 
Figure 4-31 : Predicted CNBr digestion of σ-A.  The domain structure 
of σ-A (top) is shown with the predicted CNBr digestion fragments below. 
Note that the fragment containing region 1.1 (2-125) is more than twice as 
large as the next largest fragment (176-236). 
   
 Crosslinker 4.5 was attached to a subset of the σ-A cysteine mutants and 
samples were irradiated with 325 nm laser light.  Samples were then digested 
with CNBr, resolved by non-reducing SDS-PAGE and analyzed by Western blot 
with streptavidin-HRP (Figure 4-32).  As the disulfide bond had not been 
reduced, the biotin tag remained attached to region 1.1.  Four biotin containing 
bands were observed in all samples.  We reasoned that the smallest represented 
the CNBr fragment 2-125.  The gel mobility was more consistent with a 22 kDa 
protein than a 14.5 kDa protein.  However, region 1.1 displays aberrant gel 
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mobility.  For instance, see Figure 4-22 in which σ-A(1-95) migrates as a 15 kDa 
protein even though its actual mass is 11.3 kDa.  We interpret the larger 
fragments as partial digestion products containing region 1.1, likely 2-150, 2-175 
and 2-236.  Additionally, some higher molecular weight biotin containing species 
were observed in the UV irradiated D60C mutant.  These most likely represent 
interdomain crosslinks. 
 
Figure 4-32 : Identification of region 1.1 containing CNBr fragments.  
Crosslinker was attached to the indicated σ-A constructs and samples 
were treated with UV (+) or left untreated (-).  Samples were digested with 
CNBr and resolved by non-reducing SDS-PAGE (10-20% acrylamide, tris-
tricine buffer system).  Biotin containing bands were visualized by Western 
blot (Streptavidin-HRP).  The smallest biotin containing band was 
interpreted to represent the smallest region 1.1 containing CNBr fragment.  




 In order to determine to what part of the protein crosslinking had occurred, 
the crosslinked samples were digested with CNBr followed by reduction to 
transfer the biotin tag. In all samples, the crosslinker was observed on the 
fragments that contain region 1.1 (Figure 4-33). This is consistent with local 
crosslinking to nearby residues.  The presence of biotin in bands that were 
smaller than the region 1.1 containing bands were interpreted to indicate 
interdomain contacts.  E32C and S40C did not display strong crosslinking to 
fragments from any other region.  The other mutants all showed crosslinking to 
fragments that were smaller than region 1.1, and must therefore come from 
domains 2-4.  
We reasoned that if the sample was enriched for biotin containing 
fragments following CNBr digestion, we would be able to identify the crosslinked 
bands by gel extraction and mass spectrometry.  CNBr digested crosslinked 
samples of the E32C and D60C mutants (we chose to work with one mutant that 
formed inter-domain crosslinks (D60C) and one that did not (E32C)) were 
enriched by application to monomeric avidin beads.  We were unable to elute 
crosslinked sample with excess biotin, but were able to by boiling in SDS loading 
buffer.  The enriched sample revealed a more complex crosslinking pattern than 
seen before enrichment (Figure 4-34A).  Unfortunately, the enriched protein was 
not obtained in quantities that could be detected by silver stain (Figure 4-34B).  







Figure 4-33 : Interdomain crosslinks from region 1.1.  Crosslinker 4.5 
was attached at the indicated residues and samples were irradiated with 
laser light.  Samples were then digested with CNBr, separated by reducing 
SDS-PAGE (10-20% acrylamide, tris-tricine buffer system) and probed for 
biotin by Western blotting (HRP-streptavidin).  Samples that were not 
irradiated retained no biotin.  Biotin containing fragments with apparent gel 
mobility of 20 kDa or larger were interpreted to indicate local crosslinking 
to region 1.1.  Biotin containing fragments that ran as if they were smaller 










Figure 4-34 : Avidin enrichment of crosslinked samples.  The 
indicated cysteine mutants of σ-A were crosslinked and digested with 
CNBr.  Following reduction, samples were enriched using monomeric 
avidin beads.  Protein was eluted by boiling in SDS loading buffer, 
resolved by SDS-PAGE (10-20% acrylamide Tris-Tricine gel) and 
analyzed by western blot (Streptavidin-HRP, A) and by silver stain (B). 
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We next attempted to identify CNBr digestion fragments in samples that 
were not enriched for biotin.  We reasoned that biotin containing fragments could 
be identified by gel mobility.  Crosslinked, reduced samples were digested and 
run on a 20 cm gel in duplicate.  One of the replicates was blotted with HRP-
streptavidin (Figure 4-35A).  The other sample was silver stained (Figure 4-
35B), digested with trypsin and peptide fragments were extracted and identified 
by mass spectrometry.  Three fragments could be identified in this manner.  The 
region 1.1 containing band 2-150 was identified with a gel mobility consistent with 
our earlier identification in Figure 4-32.  The smallest crosslinking band was 
determined to be made up of two fragments, comprising residues 342-394 and 
342-399 and thus represents region 4.2, with some of region 4.1 included.  
Unfortunately, all other bands were found to contain tryptic fragments from 













Figure 4-35 : Crosslinking performed on large scale for MS 
identification of bands.  Indicated σ-A mutants were labeled, exposed to 
UV light and digested with CNBr.  Samples were then resolved by 
reducing SDS-PAGE (~300 µg total protein per lane, 20% acrylamide) and 
analyzed by Western blotting (A, Streptavidin-HRP) or by silver stain (B).  
Silver stained bands were excised, digested with trypsin and analyzed by 
MALDI-TOF and ESI mass spectrometry.  Three bands could be identified 
unambiguously, as indicated.  Other bands contained tryptic fragments 
that indicated that multiple species were present in each. 
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Figure 4-35 : Crosslinking performed on large scale for MS 












Figure 4-36 : Two dimensional separation of σ-A CNBr digest by RP-
HPLC and SDS-PAGE.  (A)  Wild-type σ-A was digested with CNBr and 
separated by reverse phase HPLC.  Peaks were collected and identified 
by ESI-MS.  (B) Fractions with the indicated retention time on the RP-
HPLC trace from (A) were analyzed by SDS-PAGE (10-20% acrylamide, 
tris-tricine buffer system).  A crude CNBr digest  of σ-A (Full length) is 
included for comparison.  Indicated to the right of the gel image is the 
domain structure of σ-A and identifications of fragments that could be 




Figure 4-36 : Two dimensional separation of σ-A CNBr digest by RP-
HPLC and SDS-PAGE. 
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In order to identify additional CNBr fragments, wild type σ−A was digested 
with CNBr and separated by RP-HPLC.  Individual peaks were collected, 
analyzed by mass spectrometry then lyophilized and resolved by SDS-PAGE 
(Figure 4-36).  The fragment corresponding to residues 342-394 was identified 
by mass and found to display the same gel mobility as the smallest crosslinked 
band.  Region 1.1 was also identified by this method.  It was also determined 
that, as suggested by earlier results, numerous digestion fragments co-migrate 
between 10 and 15 kDa.  This made identification of crosslinked bands based on 
gel mobility in this region difficult to impossible. 
In order to aid in the identification of crosslinked fragments, we turned to 
BNPS-skatole (2-(2'-Nitrophenylsulfenyl)-3-methyl-3-bromoinolenine) digestion, 
which cleaves following tryptophan residues.  There are three tryptophan 
residues in σ-A : W201, W213 and W214.  Thus, BNPS-skatole digestion 
effectively cuts σ-A in half (Figure 4-37).  Crosslinked protein samples were 
digested with BNPS-skatole, separated by reducing SDS-PAGE and blotted with 
streptavidin-HRP.  As expected, when crosslinker was attached to residues 32 or 
40, very little crosslinking was seen on the band representing 202/215-399.  All 
the other sites that were labeled clearly formed crosslinks with this fragment, 
indicating inter-domain crosslinking.  All eight sites of attachment crosslinked to 
the fragment comprising residues 1-201/214 (Figure 4-37) which is consistent 




Figure 4-37 : BNPS-Skatole digestion of crosslinked σ-A.  Labelled 
and crosslinked σ-A was digested with BNPS-skatole and analyzed by 
Western blot (Streptavidin-HRP, SDS-PAGE 4-12% acrylamide).  The 
D60C sample did not label well, so a longer exposure is shown to the 
right.  Strong crosslinking was detected for all samples in the fragments 
representing residues 1-201/214.  Significant crosslinking to the fragments 
representing residues 202/215-399 was not detected in E32C or S40C but 
was seen in all other samples.  Digestion fragments were identified by 
excision, digestion with trypsin and analysis by mass spectrometry (data 
not shown).  
 
To further map the interactions, a subset of the crosslinked samples were 
subjected to BNPS-skatole digestion and analyzed both by HRP-streptavidin 
blotting and by coommassie stain.  We chose E32C, F64C and E70C as 
representatives of what appears to be three distinct crosslinking patterns (Figure 
4-33).  The digested bands were cut out and extracted by boiling in ~0.5% SDS 
in 1N HCl followed by digestion with CNBr.  The two stage digestion was 
analyzed by blotting with HRP-streptavidin (Figure 4-38).  In the F64C and E70C 
mutants, the 215-399 fragment was further digested into smaller biotin containing 
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fragments.  In the case of F64C, this includes what is likely the 342-394/9 
fragment seen in the digestion of the full fragment (Figure 4-35).  From this we 
conclude that region 1.1 is interacting with region 3 or 4.  No biotin was detected 
in the extracted and digested 215-399 fragment from E32C, consistent with no 
inter-domain crosslinking occurring from this site. 
The second digestion of the fragment representing 1-201 was more 
revealing.  While E32C showed no crosslinking to smaller digestion fragments, 
F64C and E70C both displayed crosslinking to fragments which displayed greater 
gel mobility than region 1.1 (Figure 4-38C).  These can only represent digestion 
fragments containing region 2.  Thus we conclude that some sites on region 1.1 






Figure 4-38 : Mapping crosslinking pattern by sequential digestion.  
Crosslinked samples of the indicated cysteine mutants were digested with 
BNPS-skatole, separated by SDS-PAGE (4-12% acrylamide) and 
visualized by Western blot (HRP-streptavidin, A) and by coomasie stain 
(B).  All three samples crosslinked to the band representing residues 1-
201/215, but only F64C and E70C displayed significant crosslinking to the 
band representing residues 202/216-399.  (C-D) Coomasie stained, UV 
treated BNPS-skatole digestion bands from (B) were excised and 
extracted then digested with CNBr and analyzed by SDS-PAGE (10-20% 
acrylamide, tris-tricine buffer system) and Western blot (HRP-streptavidin).  
(C) CNBr digestion of 1-201/215 fragment.  E32 displayed crosslinking 
only to the parent band of 1-201/215 while F64C and E70C both displayed 
crosslinking to smaller digestion products.  As these run smaller than 
region 1.1 containing bands, they must represent fragments that contain 
region 2 (residues ~126-225).  (D) CNBr digestion of 202/216-399 
fragment.  E32C displays no crosslinking to either the parent band nor 
digestion products.  F64C and E70C display crosslinking to both the 
parent band and region 3-4 fragments.  Based on comparison to previous 
experiments (Figure 4-34, Figure 4-35), it is most likely that these are 
region 4 digestion fragments. 
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Figure 4-38 : Mapping crosslinking pattern by sequential digestion.   
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Section 4.3 : A model of group 1 σ factor regulation 
 
 Given the inability to determine a crystal structure of region 1.1, one 
possibility was that region 1.1 is essentially unstructured, acting mainly as an 
amorphous blob of negative charge.  By using NMR, we have determined that 
this is not the case.  In fact, region 1.1 does have a structured core, but this core 
is in between a flexible N-terminal tail and another flexible linker to region 2.  This 
may provide an explanation for the difficulty in crystallizing σ factors containing 
region 1.1 as well as the inability to resolve region 1.1 in the crystals that do 
contain region 1.1 [43]. 
 The residues of region 1.1 that make contacts with region 2 and region 4 
turn out to be localized to a negatively charged area (Figure 4-39, compare to 
Figure 4-14).  The only two residues tested that do not make interdomain 
contacts are both located on the neutral/slightly positive face of region 1.1.  
Region 2 and region 4, which are both DNA binding domains are positively 
charged (region 2 pI ~ 10.5; region 4 pI ~ 10).  It is therefore possible that region 
1.1 is interacting with region 2 and 4 through a simple electrostatic interaction.   
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Figure 4-39 : Interacting sites of region 1.1. Surface rendering of region 
1.1 shown in the same orientation as Figure 4-11.  Shown in red are the 
residues that were able to form crosslinks to other domains of σ-A.  Shown 
in gray are regions that only formed local crosslinks to region 1.1.  Images 
were generated using MacPYMOL (Delano Scientific). The amino acid 
sequence of the construct is shown at the top of the figure with 
interdomain crosslinking residues in red and residues that display only 
local crosslinking in gray. 
 
 We could not detect crosslinks that could be definitively mapped to region 
3, but we cannot fully rule them out as absence of evidence is not necessarily 
evidence of absence.  However, based on the idea that region 1.1 interacts with 
regions 2 and 4 through an electrostatic interaction, it is less likely that a region 
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1.1 – region 3 interaction is occurring.  Region 3 bears a negative charge (pI ~ 
4.5) which would make it difficult to form contacts with the also negatively 
charged region 1.1.  Although it is possible that region 3 could bind to the slightly 
positive face of region 1.1, we could not detect any crosslinking to this surface 
and conclude that no contacts are being made. 
 This leads us to propose that region 1.1 effects a compaction of the sigma 
factor in solution by binding to regions 2 and 4, as shown in Figure 4-40.  
Consistent with this model, LRET [134] and FRET [135] data has shown that 
interdomain distances in the σ factor are smaller in free σ than in the RNAP 
holoenzyme.  The autoregulatory role of region 1.1 is therefore fulfilled by locking 
the DNA binding domains in a conformation that is incompatible with DNA 
binding.  The contacts between region 1.1 and the DNA binding domains are 
likely broken and replaced by contacts between the core RNAP and σ2 - σ4, 
relieving the DNA binding inhibition and allowing transcription initiation.  In 
hindsight, the relative insolubility and instability of the σ(117-399) and σ(117-318) 
constructs used in the segmental labeling may be the result of the loss of these, 
presumably stabilizing interactions. 
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Figure 4-39 : Proposed model of DNA binding inhibition by region 
1.1.  The negative surface of σ-1.1 is capable of forming crosslinks to the 
DNA binding domains σ-2 and σ-4.  It is thus likely that σ-1.1 organizes 
the σ factor into a compacted structure that is incapable of binding DNA. 
 
We cannot, using the approaches we have, determine the strength of the 
interactions between region 1.1 and the DNA binding domains of the σ factor.  
We predict, however, that they are fairly weak, and likely relatively transient for a 
number of reasons.  First, mechanistically, the interdomain interactions need to 
be broken in order to form the DNA binding competent RNAP holoenzyme.  If the 
interactions between the sigma domains are of high affinity, it would be difficult 
and energetically expensive to form productive holoenzyme complexes due to 
effective molarity [136].  Second, while σ constructs containing region 4 could be 
inhibited by the addition of region 1.1 in trans, achieving a 50% reduction in DNA 
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binding required a 15-20 fold excess of region 1.1 over region 4 [40], suggesting 
that binding between the two domains is weak.  Additionally, region 2 binding by 
region 1.1 could not be detected in this trans inhibition assay, once again 
implying weak binding.  Finally, the NMR spectra of region 4.2 is not significantly 
perturbed by region 1.1 [119], despite the fact that our crosslinking data shows 
that region 1.1 and region 4.2 must be in close proximity.  This points to an 
interaction that is both weak and somewhat fluid, which could be difficult to detect 
when using NMR based approaches.  This highlights the sensitivity of the 
crosslinking approach as it can capture relatively weak and transient interactions. 
 
Section 4.4 : Open questions and future experiments 
 
 The most obvious remaining questions are exactly what residues in σ−2 
and σ−4 are region 1.1 contacting and whether or not region 1.1 interacts with σ-
3.  These questions could both be answered with a direct extension of the 
crosslinking approach used.  When mapping crosslinking interactions from region 
1.1, we were aided by the fact that, in a CNBr digest, region 1.1 is readily 
identified by gel mobility.  Thus, if the crosslinker was instead attached to sites on 
σ-2, σ-3 or σ-4, crosslinking to region 1.1 could be easily identified on an HRP-
streptavidin blot without the laborious digestion mapping we were forced to use in 
this study.  Numerous structures of σ-2 - σ-4 are available [41-43, 117, 118, 120-
123], which would aid in the design of cysteine mutations in these domains. 
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 Of additional interest is the position of region 1.1 in the RNAP holoenzyme 
before and after transcription initiation.  Ebright and coworkers have 
demonstrated, through the attachment of fluorescent FRET pairs that region 1.1 
is located in the active-center cleft of the RNAP in the closed conformation, 
possibly functioning as a DNA mimic [135].  When the RNAP holoenzyme 
transitions to the open complex, region 1.1 is displaced by more than 50 
angstroms.  Once again, a direct extension of our use of crosslinking could also 
address this question.  By performing the crosslinking experiment in RNAP 
holoenzyme with labeled σ-1.1 in the presence and absence of DNA, one could 
determine what subunits region 1.1 is contacting before and after transcription 
initiation. 
 Finally, left unanswered is the question of the strength of the interactions 
detected.  As they are predicted to be very weak, accurately measuring them is 
likely to be difficult.  Simply measuring a binding affinity between two domains by 
mixing them in trans would be unlikely to be informative since it has already been 
determined that the σ-1.1:σ−2 interaction cannot be formed in trans.  Additionally, 
it is quite plausible that the σ-1.1:σ−2 and the σ-1.1:σ−4 interactions may function 
cooperatively.  If so, then binary domain:domain affinity measurements would not 
be meaningful.  The most accurate measure of the strength of interaction would 
probably be to measure and sum the denaturation energies of σ-1.1 and σ−Δ1.1 
separately and then compare that to the denaturation energy of full length σA.   
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Any energetic difference found could be attributed to the compaction of the 
protein effected by σ-1.1. 
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Chapter 5 : Summary and Conclusions 
 
 An ideal conditional protein allele is one that is activated rapidly, and in a 
dosable manner and whose activity is indistinguishable from wild-type activity.  
An ideal method of generating conditional protein alleles should also be general 
in that the generation of a conditional allele of any protein target should require 
minimal optimization.  Most of my thesis work was spent developing two novel 
methods for the generation of conditional protein alleles. 
 The first technique is an extension of CPS (Figure 2-2) which prior to this 
work had been used only to tag proteins [74, 83] and to relieve autoinhibition of 
an enzyme in vitro [84].  We demonstrated that an enzyme that was inactivated 
by splitting it into two fragments could be activated by splicing the inactive 
fragments together to generate full length protein.  This technique proved 
effective (Figure 2-8A and Figure 2-9), fast (Figure 2-8C), dosable (Figure 2-
10) and applicable to animal studies (Figure 2-11).  Unfortunately, CPS was 
difficult to apply to new protein targets, due to the sequence and context 
dependence of splicing sites (Figure 2-14 and Figure 2-16).  However, the 
search for a splicing site in a target protein may be streamlined by the use of 
library screening methods such as those shown in Figure 2-17 and Figure 2-18. 
 The second technique was developed in response to the difficulty in 
generating CPS alleles of new protein targets.  We reasoned that if we could 
avoid the splicing reaction, we could avoid the sequence dependence that came 
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along with it.  We turned to the idea of rescuing destabilized proteins, which 
Crabtree and Wandless have demonstrated is a general means of generating 
conditional alleles [30-32].  However, the techniques described by Crabtree and 
Wandless result in the rescue of an FRB or FKBP fusion protein rather than the 
wild type protein.  In some cases, this may not be an issue, but for others, the 
fusion protein may not display wild type activity.  As such we developed the 
SURF technology (Figure 3-1) which activates protein activity by removing a 
destabilizing sequence rather than by stabilizing it. 
 In contrast to the CPS system, it was relatively easy to generate SURF 
alleles of a variety of proteins in mammalian cells (Figure 3-2, Figure 3-5, 
Figure 3-6, Figure 3-8).  In S2 cells, we were able to generate a SURF allele of 
luciferase (Figure 3-12) but were unable to generate SURF alleles of DBT or 
SGG (Figure 3-13 and Figure 3-14).  Although this does mean that SURF is not 
a completely general technology, we are inclined to believe that, given the 
domain structure of DBT and SGG, they represent uncommon exceptions to the 
generality of SURF.  The only drawback to SURF alleles is that their activation is 
slow when compared to CPS since SURF alleles require new protein synthesis 
for activation. 
 In addition to my work on conditional protein alleles, I have also worked on 
the characterization of region 1.1 of bacterial σ-70 like factors.  The function of 
this domain has long been mysterious, in large part due to the lack of a high 
resolution structure.  We generated a high resolution structure based on NMR 
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spectroscopy and provided evidence by segmental NMR and interdomain 
crosslinking that inhibition of DNA binding is achieved by direct binding of region 
1.1 to the DNA binding domains σ-2 and σ-4.  
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Chapter 6 : Materials and Methods 
Section 6.1 : CPS 
Plasmid Construction 
 Constructs used in chapter 2 are shown Table 6-1. Constructs were 
cloned by standard methods and confirmed by sequencing. The pCre-luc plasmid 
(Promega) was used as a source of firefly luciferase.  Constructs 1 and 2 from 
reference [83] were used as sources of the split VMA intein, FKBP/FRB domains 
and MBP. Renilla luciferase transfection control was cloned from pRL-SV40 
(Promega).  N-luc and C-luc intein mutants were generated by mutating the first 
(C1) and last (N454) residues of the VMA intein to alanine using Quikchange 
(Stratagene) mutagenesis. Oligonucleotides were purchased from Integrated 
DNA Technologies.  Sequencing was performed by GENEWIZ. Constructs were 
cloned into one or more of the following vectors : pcDNA3+ (Invitrogen), pUAST 
[137], or pAc5.1/V5-His (Invitrogen). 
Table 6-1 : Constructs used in Chapter 2. 
Construct Sequence Vector 
Luc(1-436) Flag tag – GGRVGK - Luciferase(1-
436) - VMA (1-182) - 
LYSRNNGNGNGTR - FKBP 
pAc5 
Luc(437-551) Flag tag - GGRSH - FRB - VMA (390-
454) – Luciferase(437-551 R437C) 
pAc5 
MBP-IN-FKBP MBP - 
SSSNNNNNNNNNNLGIEGRISEFLKG 
- VMA (1-182) - LYSRNNGNGNGTR - 
FKBP 
pAc5 
N-luc Flag tag – GGRVGK - Luciferase(1-
490 H489K) - VMA (1-182) - 
LYSRNNGNGNGTR - FKBP 





C-luc Flag tag - GGRSH - FRB - VMA (390-





C-lucFRB2 Flag tag - GGRSH - FRB - FRB - VMA 






C-lucFRB3 Flag tag - GGRSH - FRB - FRB - FRB 
- VMA (390-454) - Luciferase(491-551 
K491C) 
pAc5 
Luc(1-507) Flag tag – GGRVGK - Luciferase(1-
507 T507G) - VMA (1-182) - 
LYSRNNGNGNGTR - FKBP 
pAc5 
Luc(508-551) Flag tag - GGRSH - FRB - VMA (390-
454) – Luciferase(508-551 T508C) 
pAc5 
Luc(1-215) Flag tag – GGRVGK - Luciferase(1-
215) - VMA (1-182) - 
LYSRNNGNGNGTR - FKBP 
pAc5 
Luc(216-551) Flag tag – GGRVGK - FRB - VMA 
(390-454) – Luciferase(216-551) 
pAc5 
Luc(1-184) Flag tag – GGRVGK - Luciferase(1-
184 E184G) - VMA (1-182) - 
LYSRNNGNGNGTR - FKBP 
pAc5 
Luc(185-551) Flag tag – GGRVGK - FRB - VMA 
(390-454) – Luciferase(185-551 
S185C) 
pAc5 
Luc(1-80) Flag tag – GGRVGK - Luciferase(1-80 
A79G) - VMA (1-182) - 
LYSRNNGNGNGTR - FKBP 
pAc5 
Luc(81-551) Flag tag – GGRVGK - FRB - VMA 
(390-454) – Luciferase(81-551) 
pAc5 
Luc(1-297) Flag tag – GGRVGK - Luciferase(1-
297) - VMA (1-182) - 
LYSRNNGNGNGTR - FKBP 
pAc5 
Luc(298-551) Flag tag – GGRVGK - FRB - VMA 
(390-454) – Luciferase(298-551 
S298C) 
pAc5 
Dbt(1-266) MBP - 
SSSNNNNNNNNNNLGIEGRISEFLKG 
- Dbt(1-266) - VMA (1-182) - 
LYSRNNGNGNGTR - FKBP 
pAc5 




- FRB - VMA (390-454) – Dbt(267-
441) 
Dbt(1-95) MBP - 
SSSNNNNNNNNNNLGIEGRISEFLKG 
- Dbt(1-95) - VMA (1-182) - 
LYSRNNGNGNGTR - FKBP 
pAc5 
Dbt(96-441) MBP - 
SSSNNNNNNNNNNLGIEGRISEFLKG 
- FRB - VMA (390-454) – Dbt(96-441) 
pAc5 
Dbt(1-281) MBP - 
SSSNNNNNNNNNNLGIEGRISEFLKG 
- Dbt(1-281) - VMA (1-182) - 
LYSRNNGNGNGTR - FKBP 
pAc5 
Dbt(282-441) MBP - 
SSSNNNNNNNNNNLGIEGRISEFLKG 
- FRB - VMA (390-454) – Dbt(282-441 
F282C) 
pAc5 
Dbt(1-310) MBP - 
SSSNNNNNNNNNNLGIEGRISEFLKG 
- Dbt(1-310) - VMA (1-182) - 
LYSRNNGNGNGTR - FKBP 
pAc5 
Dbt(311-441) MBP - 
SSSNNNNNNNNNNLGIEGRISEFLKG 
- FRB - VMA (390-454) – Dbt(311-441 
A311C) 
pAc5 
Dbt(1-351) MBP - 
SSSNNNNNNNNNNLGIEGRISEFLKG 
- Dbt(1-351) - VMA (1-182) - 
LYSRNNGNGNGTR - FKBP 
pAc5 
Dbt(352-441) MBP - 
SSSNNNNNNNNNNLGIEGRISEFLKG 
- FRB - VMA (390-454) – Dbt(352-441 
S352C) 
pAc5 
Dbt(1-366) MBP - 
SSSNNNNNNNNNNLGIEGRISEFLKG 
- Dbt(1-366) - VMA (1-182) - 
LYSRNNGNGNGTR - FKBP 
pAc5 
Dbt(367-441) MBP - 
SSSNNNNNNNNNNLGIEGRISEFLKG 






S2 cell culture experiments 
Drosophila Schneider’s Line 2 (S2) cells were maintained in M3 media 
(Sigma) supplemented with Fetal Bovine Serum (Sigma, 15%) and 
Penicillin/Streptomycin (Invitrogen, 93U/mL & 93µg/mL) at 25 °C.  Cells were 
transfected with 500 ng of each plasmid (500 ng of empty vector was added in 
the case of single transfections) and 100 ng of renilla luciferase control when 
appropriate using the Qiagen Effectene protocol. Following 16h of expression at 
25 °C, cells were aliquoted into 1.5 mL microcentrifuge tubes and treated with 
DMSO (Sigma, 0.1% final concentration) or with rapamycin (Sigma, 100 µM in 
DMSO, 100 nM/0.1% DMSO final concentration) for 4 h unless otherwise stated. 
Cells were then pelleted by centrifugation, media was removed and cells were 
lysed with 1x Passive Lysis Buffer (PLB, Promega) supplemented with 1 mM 
ZnCl2 to prevent splicing after lysis [83]. Luciferase readings were performed in a 
Berthold Sirius luminometer using the Promega Dual-luciferase assay kit. In the 
ascomycin competition experiment, cells were initially treated with rapamycin (5 
µM in DMSO, 5 nM/0.1% DMSO final concentration) followed by ascomycin 
(Sigma) at the indicated time points without changing media (500 µM in DMSO, 
final concentrations: 5 nM rapamycin/500 nM ascomycin/0.2% DMSO). 
Mammalian cell culture experiments 
HeLa cells were cultured in Dulbeco’s Modified Eagle Medium (DMEM, 
Gibco) supplemented with 10% FBS (Sigma) at 37 °C and 5% CO2 according to 
standard procedures.  Cells were transfected using FuGENE-6 (Roche Applied 
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Science).  Plasmid DNA (250 ng of N-luc and C-luc constructs and 25 ng of the 
renilla control pRL-SV40 (Promega) per 1 mL, twelve-well plate) was mixed in a 
1:3 ratio with the FuGENE reagent in DMEM and was then applied to cells 
growing in DMEM/10% FBS.  Transfection was allowed to proceed 16 h before 
replacement with fresh media containing DMSO (Sigma, 0.1% final 
concentration) or with rapamycin (Sigma, 100 µM in DMSO, 100 nM/0.1% DMSO 
final concentration) for 4 h. After the indicated drug treatments, cells were 
washed twice with PBS (137 mM NaCl, 2.7 mM KCl, 10mM Na2HPO4, 2 mM 
KH2PO4 (pH 7.4)) and lysed with 1x Passive Lysis Buffer (PLB, Promega) for 15 
min at rt.  Following centrifugation for 10 min at 10 g, luciferase readings were 




 Protein samples in SDS loading buffer (50 mM Tris⋅HCl, 2% (w/v) SDS , 
0.1% (w/v) bromophenol blue, 10% (v/v) glycerol, 100 mM DTT) were separated 
by SDS-PAGE before being transferred to PVDF (Biorad) using standard western 
blotting procedures.  The anti-luciferase antibody (Cambridge Antibodies) was 
used at 1:15000. The anti-MBP antibody (New England Biolabs) was used at 
1:5000.  Loading was normalized to transfection efficiency by loading an equal 
amount of Renilla luciferase activity.  Western blots were blocked in TBST (10 
mM Tris (pH 8.0), 150 mM NaCl, 0.1% Tween 20) containing 5% dry milk for 1 h, 
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followed by incubation with the appropriate primary antibody in blocking buffer for 
an additional 1 h at rt or overnight at 4 °C.  After washing three times with TBST, 
the blots were incubated with HRP-conjugated secondary antibodies (Amersham 
Bioscience for anti-rabbit, Cambridge Antibodies for anti-goat) for 1 h in blocking 
buffer, washed three more times with TBST, and developed using ECL reagents 
(Perkin Elmer) and Kodak Biomax MR film. 
Transgenic Flies 
N-luc and C-luc were cloned into the pUAST [137] vector.  20µg of each 
was co-precipitated with 5µg of the wings-clipped plasmid [138] and resuspended 
in sterile water.  Dechorionated yw embryos were injected with the plasmid 
mixture and covered with Halocarbon brand 27 oil at 18 °C. Upon emerging, 
larvae were placed on fresh fly food and grown to adulthood at room 
temperature.  Adult flies were backcrossed to yw flies and w+ offspring were 
selected and balanced using standard methods.  C-lucFRB2 flies were generated 
and balanced using standard methods (BestGene, Inc.). 
N-luc insertions into the 2nd and 3rd chromosome were crossed with flies 
containing P-element GAL4 insertions under the armadillo and timeless 
promoters respectively.  Third chromosome crossover products containing N-luc 
and armadillo-GAL4 and second chromosome crossover products containing N-
luc and timeless-GAL4 were selected by screening for luciferase activity following 
breeding with C-luc insertions into the second and third chromosomes 
respectively. 
 191 
 Male flies (female flies had similar readings, data not shown) homozygous 
for N-luc, C-luc and a GAL4 driver as well as yw flies and flies expressing full 
length luciferase under the timeless promoter were deprived of food for 1 hour 
and then placed on fly food supplemented with 100 µM rapamycin (2% DMSO) 
and 200 µM luciferin (Sigma) and placed in a Hamamatsu Photon detection unit 
maintained at room temperature.  Luciferase readings were taken in 1 minute 
bins every 12 minutes for up to 4 days. 
 For western blotting, flies were deprived of food for 1 hour and then placed 
on 3MM filter paper soaked in 40% glucose supplemented with 100µM 
rapamycin (2% DMSO) for 12h.  Individual flies were homogenized in PLB with 1 
mM ZnCl2.  Protein concentration in fly lysates was determined by the Bradford 
assay (Biorad).  5 µg of total protein was loaded from each fly lysate.  A non-
specific band served as a control for transfer efficiency. 
 
Section 6.2 : SURF 
Plasmid construction 
SURFn and SURFc constructs were prepared using standard molecular 
cloning techniques.  Constructs 1 and 2 from reference [74] were the sources of 
the FRB and FKBP domains, ubiquitin cDNA (Sigma) was the source of ubiquitin, 
pCre-luc plasmid (Promega) was the source of luciferase, pcDNA3-Casp3-myc 
(Addgene) was the source of caspase-3, pHA-Smad3 was the source of 
Smad3E, Salmonella Ty. genomic DNA was the source of SopE, and pLNCX 
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chick src (Addgene) was the source of v-Src. The final architectures of all 
constructs are shown in Table 6-2. FRB refers to the single mutant (T2098L) 
used in chapter 2, FRB* refers to the triple mutant (K2095P, T2098L, W2101F).  
All N-terminal ubiquitin constructs contain an I13A mutation.  In our hands, split 
ubiquitin of wild-type sequence displayed constitutive complementation in 
mammalian cells, whereas the I13G mutant resulted in no inducible cleavage 
(data not shown).  All constructs were characterized by DNA sequencing 
(Genewiz). Stabilization mutants were generated by mutating the residue 
immediately following ubiquitin in the C-terminal constructs to proline using 
Quikchange (Stratagene) mutagenesis. 
Table 6-2 : Constructs used in Chapter 3 
Construct Sequence Vector 











































































Mammalian Cell Culture Experiments   
HeLa and SYF cell lines were cultured in Dulbeco’s Modified Eagle 
Medium (DMEM, Gibco) supplemented with 10% FBS (Sigma) at 37 °C and 5% 
CO2 according to standard procedures.  Cells were transfected using FuGENE-6 
(Roche Applied Science).  Plasmid DNA (250 ng of SURFn and SURFc 
constructs and 25 ng of reporter construct and/or 25 ng of the renilla control pRL-
SV40 (Promega) per 1 mL, twelve-well plate) was mixed in a 1:3 ratio with the 
FuGENE reagent in DMEM and was then applied to cells growing in DMEM/10% 
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FBS.  In the time course experiments, transfection was allowed to proceed for 24 
h before replacement with fresh media containing DMSO (Sigma, 0.1% final 
concentration) or with rapamycin (Sigma, 100 µM in DMSO, 100 nM/0.1% DMSO 
final concentration) for the indicated time points.  For all other experiments the 
above transfection mixture was applied to cells growing in DMEM/10% FBS 
containing DMSO (0.1% final concentration), rapamycin (Sigma) and/or 
ascomycin (Sigma) in DMSO (0.1% - 0.2% final concentration) where 
appropriate.  After 12 h, fresh medium for continued drug treatment was added.  
When indicated, Cells were treated with the proteasome inhibitor ZL3VS [95] for 
6 h. 
Luciferase Measurements 
After the indicated drug treatments, cells were washed twice with PBS and 
lysed with 1x Passive Lysis Buffer (PLB, Promega) for 15 min at rt. Following 
centrifugation for 10 min at 10 g, luciferase readings were performed in a 
Berthold Sirius luminometer using the Promega dual-luciferase assay kit. 
MTT cell proliferation assay  
The MTT cell proliferation assay was purchased from American Tissue 
Culture Collection (ATCC) and performed as per the manufacturer’s instructions. 
Briefly, SYF cells were tranfected with appropriate plasmids as above.  After 24 h 
to allow for protein expression, the cells were trypsinized, counted, and ~1 X 104 
were plated in 96 well plates in DMEM containing 10% FBS and rapamycin (100 
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nM) or DMSO where appropriate. After an additional 24 h to allow for rescue, the 
MTT cell proliferation assay was performed. 
 
S2 cell culture experiments 
 Cell line maintenance, transfection, drug treatment and harvesting was 
performed as described in Section 6.1.  
  
Western Blotting 
Mammalian cells were washed twice with PBS and lysates prepared using 
NP buffer (50 mM Tris [pH 7.4], 0.5% NP40, 5 mM MgCl2, protease inhibitor 
cocktail [Roche Applied Science]).  Total protein concentrations were normalized 
by Bradford assay (BioRad) and NP lysates were then mixed 3:1 with 4X SDS 
loading buffer and separated by SDS-PAGE before being transferred to PVDF 
(Biorad) using standard western blotting procedures.  S2 cell westerns were 
performed as described in Section 6.1.  The anti-HA antibody (Roche Applied 
Science) was used at 1:10000. The anti-MBP antibody (New England Biolabs) 
was used at 1:5000.  Anti-avian Src (clone EC10, Upstate) was used at 1:1000.  
The anti-phosphotyrosine (Calbiochem) was used at 1:1000.  Anti-
phosphotryrosine western blots were blocked in TBST containing 5% BSA for 1 
h.  All other western blots were blocked in TBST containing 5% dry milk for 1 h, 
followed by incubation with the appropriate primary antibody in blocking buffer for 
an additional 1 h at rt or overnight at 4 °C.  After washing three times with TBST, 
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the blots were incubated with HRP-conjugated secondary antibodies (Amersham 
Bioscience) for 1 h in blocking buffer, washed three more times with TBST, and 
developed using ECL reagents (Perkin Elmer) and Kodak Biomax MR film. 
 
Section 6.3 : σ factor 
NMR samples 
T. maritima σ-A region 1.1 (residues 1-96 or 1-116, with mutations Q21L, 
E22V, Q23P, K24R, E25G, T26S, L27H, P28M to install a thrombin site and 
mutations S96G or S116G to facilitate intein thiolysis and expressed protein 
ligation) was cloned into the pTXB1 vector (New England Biolabs) to generate a 
fusion construct of σ-A region 1.1 – Mxe GyrA intein – chitin binding domain.  BL-
21(DE3) (Invitrogen) cells were transformed with this construct, grown overnight 
on LB plates (100 µg/mL ampicillin) then grown in 1L M9 minimal media (100 
µg/mL ampicillin) with 1.2g 15NH4SO4 and 2g 13C glucose as the only nitrogen and 
carbon sources.  The culture was grown at 37 °C to an OD600 of ~0.6.  Expression 
was induced with 0.8 mM IPTG and was carried out at 30 °C for 4.5 h.  Bacteria 
were harvested by centrifugation, resuspended in lysis buffer (500 mM NaCl, 20 
mM Tris pH 8.0, 1 mM EDTA) and lysed using a french press.  The lysate was 
centrifuged and the supernatant applied to a chitin bead column (New England 
Biolabs) and washed extensively with lysis buffer.  Intein cleavage was induced 
with 50 mM DTT in lysis buffer and allowed to proceed overnight at 4 °C with 
gentle rocking.  Cleaved protein was eluted with lysis buffer and was exchanged 
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into 1x PBS by dialysis.  Thrombin protease (Amersham) was added (50 U) and 
proteolysis was carried out overnight at room temperature with gentle rocking.  
The resulting protein was H2N-GSHM-(σ-A 29-95/115)-G-COOH. The sample 
was further purified by ion exchange chromatography (Hiprep Q16/10 column, 
AKTA FPLC, Amersham) using a 0.1-1M NaCl gradient in 20 mM Tris⋅HCl (pH 
8.0).  Protein samples were characterized by electrospray mass spectrometry 
(ESMS, Sciex API-100 single quadropole electrospray mass spectrometer, see 
Figure 4-8 and Figure 4-22).  The protein sample was treated at 65 °C for 30 
min to eliminate E. coli proteases and other contaminants and then concentrated 
in NMR buffer (10 mM NaPi pH 6.5, 100 mM NaCl, 1mM EDTA) to a final 
concentration of 300-800 µM depending on the sample (sample shown in Figure 
4-9 is 370 µM, sample shown in Figure 4-23 is 300 µM).  Protein concentrations 
were determined using Bradford assay (BioRad) using a BSA  (New England 
Biolabs) standard curve. 
 
NMR 
All NMR experiments were recorded at 298 K using 600, 700 and 800 
MHz Bruker Avance NMR spectrometers equipped with cryoprobes.  All NMR 
data were processed using Topspin 1.1 (Bruker) and analyzed by NMRView 
[139].  1H chemical shifts were referenced to water at 4.75 ppm (at 25 °C) 
whereas the γ13C/γ1H and γ15N/γ1H ratios were used for indirect referencing of the 
13C and 15N chemical shifts. 1H-15N-HSQC, 1H-13C-HSQC, 3D-15N-NOESY-HSQC, 
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HNCO, HNCACB, CBCA(CO)NH experiments were used to obtain the sequential 
assignment of the backbone [140]. Side-chain carbon and proton assignments 
were obtained using C(CO)NH, HC(CO)NH, HBHA(CO)NH and HCCH-TOCSY 
experiments. For assigning the aromatic resonances, 1H-13C HSQC, 
(Hβ)Cβ(CγCδ)Hδ and (Hβ)Cβ(CγCδCε)Hε [141], and 3D 13C NOESY-HSQC data 
was utilized.  
 
Structure Calculations 
The backbone dihedral angles (φ and ψ) were calculated by analyzing the 
13Cα, 13Cβ, 13C′ and 15N chemical shifts with the TALOS program that predicts the 
backbone torsion angles from the amino acid sequence and chemical shift 
information [142].  Hydrogen bond restraints were inferred from slow H/D 
exchange of backbone amides.  Distance restraints were derived from 3D 13C-
edited NOESY and 3D 15N-edited NOESY experiments.  Using NMRView, the 
NOESY cross peak volumes/intensities were obtained and converted into 
distance restraints using the symmetry ambiguous distance restraints (ADR) 
protocol within the ARIA program [143, 144].  Structure calculations were 
performed using the Cartesian dynamics simulated anneling protocol within 
ARIA/CNS.  Lowest energy structures were further refined in water using the 
protocol described by Linge et al [145].  The NMR structures were analyzed 
using PROCHECK [146].  The electrostatic potentials were calculated using 




Expressed Protein Ligation 
Region 1.1 (residues 1-116, with mutations described above) was 
expressed in IL M9 minimal media (100 µg/mL ampicillin) in 2H2O with 1.2 g 
15NH4SO4 and 2 g 13C glucose as the only nitrogen and carbon sources, 
respectively.  Region 1.1 (residues 1-96, with mutations described above) was 
expressed in LB media (100 µg/mL ampicillin) using the construct described in 
the NMR sample section above.  Protein expression was induced and samples 
were immobilized on chitin beads as described in the NMR samples section. 
Thrombin protease (Amersham) was added (50U) and proteolysis was carried 
out on column overnight at room temperature with gentle rocking.  Intein 
cleavage was induced with 3% (vol/vol) EtSH in lysis buffer and allowed to 
proceed overnight at room temperature.  Region 1.1 thioester was eluted with 3% 
(vol/vol) EtSH in lysis buffer and concentrated to 100-250 µM (concentrations 
determined using Bradford assay).   
C-terminal fragments (residues 117-399, S117C; 117-318, S117C and 97-
399, S97C) were cloned into the pET15B vector (Novagen).  Final sequences 
were MGSS - his tag – SSGLVPRGSHM – Factor Xa site (IEGR) followed by the 
indicated σ-A residues.  BL-21(DE3) cells were transformed with these constructs 
and grown in LB broth (100 µg/mL ampicillin) at 37 °C to an OD600 of ~0.6.  
Protein expression was induced with 0.8 mM IPTG at 37 °C for 4-6 h.  Bacteria 
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were harvested by centrifugation, treated at 65 °C for 20 minutes lysed using a 
french press and purified using the Ni-NTA system (Novagen).  A buffer 
exchange to 1x PBS was performed using centrifugal filter devices (Amicon, 
5,000 MWCO).  N-terminal cysteine was exposed by treatment with Factor Xa 
protease (Amersham) in 1x PBS supplemented with 1 mM DTT overnight at room 
temperature.  Factor Xa digestions were purified by ion exchange 
chromatography (Hiprep SP16/10 column, AKTA FPLC, Amersham) using a 0.1-
1M NaCl gradient in 20 mM Tris⋅HCl (pH 6.5).  Samples were buffer exchanged 
into 10 mM CHAPSO (Sigma) in 1x PBS using a centrifugal filter device (Amicon, 
10,000 MWCO) and concentrated to ~20-100 µM.  The presence of CHAPSO in 
the samples seemed to result in unreliable readings using the Bradford assay, so 
protein concentrations can only be considered approximate.  When possible, 
protein concentration was also estimated by examination of coomassie stained 
acrylamide gels. 
EPL reactions were performed in 1x PBS with 100 mM MESNa, 1 mM 
EDTA, 3% (vol/vol) EtSH at room temperature with gentle rocking.  It was 
empirically determined that a 1:1 molar ratio between the thioester containing 
fragment and the N-terminal cysteine containing fragment resulted in the greatest 
yield.  The two fragments were present at the highest concentration possible, 
generally 20-25 µM. In the reaction shown in Figure 4-19 the concentrations of 
the fragments is ~20 µM.  In the reaction shown in Figure 4-24 the 
concentrations of the fragments is ~25 µM.  Reaction mixtures were purified by 
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ion exchange chromatography (Hiprep SP16/10 column, AKTA FPLC, 
Amersham) using a 0.1-1M NaCl gradient in 20 mM Tris⋅HCl (pH 6.5) and 
concentrated in NMR buffer containing 5 mM CHAPSO. 
 
SDS-PAGE analysis 
SDS-PAGE analysis of constructs used for all NMR studies was performed 
on 12 or 15% acrylamide (1% SDS), Tris-glycine buffered gels.  SDS-PAGE 
analysis in the crosslinking section was performed using the Criterion system 
(Biorad) except in the case of the experiment shown in Figure 4-35.  Criterion 
gels used were 4-12% acrylamide Bis-Tris buffered gels and 10-20% acrylamide 
Tris-tricine buffered gels, as indicated.  The experiment shown in Figure 4-35 
was performed on a 20% acrylamide (1% SDS) Tris-glycine buffered gel. 
Samples for western blotting were separated by SDS-PAGE before being 
transferred to PVDF (Biorad) using standard western blotting procedures.  The 
membrane was blocked in 5% milk in TBST for 1 hour at room temperature then 
washed 3 times with TBST and incubated with Streptavidin-HRP (GE Health 
Sciences, 1:5000 in TBST) for 1 hour.  The membrane was washed 3 more times 








Abortive Initiation Reactions 
 
Reactions were performed in 10 µL of transcription buffer (20 mM Tris-HCl 
(pH 8.0); 50 nM NaCl; 5 mM MgCl2).  E. coli core RNAP (0.1 µM) was incubated 
with σ factor (0.5 µM) for 10 min. at 37 °C.  T7A1 promoter fragment (0.1 µM) 
was then added and the mixture was incubated at 37 °C for a further 5 min.  
Reactions were initated by the addition of 0.5 mM CpA initiating dinucleotide and 
1 µL of α-32P-UTP.  The reactions proceeded for 15 min. at 37 °C then were 
terminated by the addition of an equal volume of gel loading buffer (7 M urea; 90 
mM Tris; 64.6 mM boric acid; 2.5 mM EDTA (pH 8.3)).  Reaction products were 
separated by polyacrylamide gel electrophoresis on a 25% gel in 7 M urea and 
visualized by autoradiography. 
 
Crosslinker Synthesis 
 All chemical reagents were purchased from Sigma or Aldrich and used 
without further purification. Boc-Cys(NPys)-OH was purchased from Bachem and 
4-azido-2,3,5,6-tetra-fluoro-benzoic acid and PEO-biotin were purchased from 
Pierce.  Thin-layer chromatography was carred out using EMD silica gel plates.  
Flash chromatography was performed using Sigma-Aldrich 60 Å 230-400 mesh 
silica gel. All solvents were concentrated using rotary evaporation.  All 1H and 13C 
NMR spectra were acquired on Bruker AM-400 MHz spectrometer.  All 1H 
chemical shifts are reported in δ referenced to solvent.  Coupling constants (J) 
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are reported in Hz. Electrospray (ESI±) spectra were obtained on a Waters 
Micromass ZQ LC/MS. 
 
Compound 4.1  To Boc-Cys(NPys)-OH (500 mg, 1.33 mmol) dissolved in DMF 
(5 mL) was added pyridine (120 µL, 1.46 mmol) followed by pentafluorophenyl 
trifluoroacetate (260 µL, 1.53 mmol).  After 45 min the reaction was diluted with 
ethyl acetate (50 mL) and washed with 1N HCl (50 mL, 2 times), conc. NaHCO3 
(50 mL, 2 times), H20 (50 mL), and brine (50 mL).  The organic layer was dried 
over Na2SO4, filtered, and concentrated.  Silica gel chromatography (20% ethyl 
acetate in hexanes) yielded 610 mg (85%) of 4.1 as a pink solid that was used in 
the next reaction with no further characterization. 
 
Compound 4.2  To a solution of PEO-biotin (50 mg, 0.12 mmol) in DMF (2 mL) 
was added diisopropylethylamine (25 µL, 0.14 mmol).  After stirring for 15 min a 
solution of 4.1 (50 mg, 0.12 mmol) in DMF (2 mL) was added and the reaction 
allowed to stir for 16 h.  At this time the reaction was concentrated and purified by 
silica gel chromatography (14:2:1 ethyl acetate:MeOH:H2O) to yield 77 mg (83%) 
of 4.2 as a tan foam.  ESI-MS calculated for C31H49N7O10S3 [M + H]+ 776.27, found 
776.90. 
 
Compound 4.3  Compound 4.2 (60 mg, 0.08 mmol) was dissolved in 95% 
trifluoroacetic acid in H2O (5 mL) and stirred for 1 h.  At this time the reaction was 
 204 
concentrated and azeotroped with toluene (10 mL, 3 times) to yield 50 mg (94%) 
of 4.3 as a waxy solid that was used directly in the next step. 
 
Compound 4.4  To a solution of 4-azido-2,3,5,6-tetrafluorobenzoic acid (50 mg, 
0.21 mmol) in DMF (5 mL) was added pyridine (19 µL, 0.24 mmol) and 
pentafluorophenyl trifluoroacetate (42 µL, 0.25 mmol).  After 45 min the reaction 
was diluted with ethyl acetate (10 mL) and washed with 1N HCl (10 mL, 2 times), 
conc. NaHCO3 (10 mL, 2 times), H20 (10 mL), and brine (10 mL).  The organic 
layer was dried over Na2SO4, filtered, and concentrated to yield 67 mg (80%) of 
4.4 that was used directly in the next step. 
 
Compound 4.5  Diisopropylethylamine (10 µL, 0.06 mmol) was added to a 
solution of 4.3 (35 mg, 0.05 mmol) in DMF (1 mL).  After 15 min a solution of 4.4 
(24 mg, 0.06 mmol) in DMF (1 mL) was added and the reaction stirred for 16 h.  
The mixture was then concentrated and purified by silica gel chromatography 
(14:2:1 ethyl acetate:MeOH:H20) to yield 32 mg (74%) of 4.5 as an off-white 
foam.  1H NMR (400 MHz, CD3OD) δ 9.00 (d, 1 H, J = 3.3 Hz), 8.73 (d, 1 H, J = 
7.0 Hz), 7.64 (dd, 1 H, J = 4.6, 8.1 Hz), 5.02 (t, 1 H, J = 7.6 Hz), 4.60 (dd, 1 H, J 
= 4.9, 7.6 Hz), 4.42 (dd, 1 H, J = 4.4, 7.7 Hz), 3.65 (app t, 6 H, J = 5.4 Hz), 3.48 
(app t, 6 H, J = 5.9 Hz), 3.32-3.27 (m, 4 H), 3.03 (dd, 1 H, J = 4.9, 12.7 Hz), 2.80 
(app d, 1 H, J = 12.7 Hz), 2.27-2.22 (m, 4 H), 1.85-1.66 (m, 5 H), 1.57-1.52 (m, 2 




T. maritima σ-A was cloned into pET15B (Novagen) with an N-terminal 
hexahistidine tag and a thrombin recognition site for removal of the affinity tag 
(Final sequence : MGSSHHHHHHSSGLVPRGSH - σ-A).  Cysteine mutants 
(Table 4-3) were generated using the Quikchange II XL kit (Stratagene).  BL-
21(DE3) cells were transformed with wild-type or mutant Sigma A and grown in 
LB broth (100 µg/mL ampicillin) at 37 °C to an OD600 of ~0.6.  Protein expression 
was induced with 0.8 mM IPTG at 37 °C for 4-6 h.  Bacteria were harvested by 
centrifugation, treated at 65 °C for 20 minutes lysed using a french press and 
purified using the Ni-NTA system (Novagen).  Protein samples were then 
transferred to 1x PBS by dialysis and treated with thrombin protease (Amersham, 
50 U) overnight at room temperature.  Proteolyzed samples were further purified 
by ion exchange chromatography (HiTrap SP HP, Amersham) with a 0.1-1M 
NaCl gradient in 20 mM Tris⋅HCl (pH 8.0).  Fractions containing protein were 
concentrated and stored at -80 °C in 10% glycerol. 
 
Attachment of crosslinker and crosslinking 
The crosslinker 4.5 was attached to the purified cysteine mutant of σ-A by 
disulfide exchange.  Reaction mixtures contained 6 µM protein and 100 µM 
crosslinker in 50 mM sodium borate (pH 8.3), 8 mM Tris-HCl (pH 8.3), 80 mM 
KCl, 0.4 mM EDTA, 5 mM methionine, 0.6 mM tyrosine, 2% glycerol and 1% 
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DMSO.  Reactions were carried out for 20 minutes at room temperature.  
Reaction mixtures were then buffer exchanged to 1x PBS using a centrifugal filter 
device (Vivascience, 10,000 MWCO) and concentrated to approximately 25 µM 
protein.  Crosslinking was then induced by treatment with a 325 nM HeCd laser 
for 10-15 seconds. 
 
Gel Shift Assay 
 5’-Fluorescein labeled T7A1 promoter DNA fragment (5’-
AGGTATTGACAACATG-3’) and the complementary, non-labeled strand were 
ordered from IDT DNA.  Oligos were suspended in 1x TE buffer and annealed by 
mixing the complementary strands (0.5 mM each), heating to 100 °C for 5 
minutes and allowing to slowly return to room temperature.  The annealed 
mixture was then diluted with 10 mM tris⋅HCl (pH 8.5) to 10 µM. Crosslinker 
labeled σ-A constructs were used from stock solutions at 20 µM in 1x PBS.  
Labeled σ-A and promoter DNA solutions were combined in a 1:1 ratio (final 
concentrations 5 µM DNA, 10 µM DNA, 0.5x PBS, 5 mM tris⋅HCl (pH 8.5)) and 
incubated at 37 °C for 10 minutes.  Glycerol was added from an 80% stock 
solution to a final concentration of 5%.  Samples were separated on a 1% 
agarose gel in 0.5x TBE and visualized by UV fluorescence (Versa Doc Model 





CNBr digestion was performed by heating protein (1 mg/mL for 
crosslinking samples, 5 mg/mL for WT sample used to identify CNBr digestion 
products) with 1.3% SDS at 42 °C for 10 minutes.  Reactions were carried out in 
0.1 N HCl, 100 mM CNBr, 1% SDS overnight at room temperature.  Reactions 
were quenched by neutralization with 1N NaOH.  
 
BNPS-Skatole Digestion 
BNPS-Skatole digestion was performed in 70% acetic acid with 3.33 
mg/mL BNPS-skatole (Sigma) overnight at room temperature.  Protein 
concentration was 0.5 µg/mL for the digests in Figure 4-37 and 1 µg/mL for the 
digests in Figure 4-38. Following overnight digestion, samples were treated with 
67mM DTT at room temperature for 20 minutes.  Samples were extracted with 
ether and aqueous fractions were lyophilized and resuspended in SDS loading 
buffer. 
 
Two Step Digestion 
BNPS-Skatole digested samples were separated by SDS-PAGE and 
visualized by coomassie stain.  Bands were excised with a clean razor blade and 
homogenized in 1N HCl, ~0.5-1% SDS with mortar and pestle then incubated at 
100 °C for 5 minutes.  Samples were digested with 100 mM CNBr overnight at 
room temperature as above. 
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Mass Spectrometry identification of CNBr digestion fragments 
 By extraction of digested fragments 
 Gel bands were excised and destained with a 1:1 solution of ferrocyanide 
(10 mg/mL) and thiosulfate (16 mg/mL) then rinsed with 50 mM NH4HCO3.  Gel 
bands were further destained in 50% acetonitrile/50mM NH4HCO3 then shrunk in 
100% acetonitrile and dried in a speed vac.  The gel band was then reduced with 
10 mM DTT in 50 mM NH4HCO3 at 56 °C for 45 minutes.  After cooling to room 
temperature, the gel band was alkylated with 100 mM iodoacetamide in 50 mM 
NH4HCO3 for 30 minutes in the dark.  The gel was then washed with 50% 
acetonitrile/50mM NH4HCO3 then shrunk in 100% acetonitrile and dried in a 
speed vac.  Trypsin (0.2 µg in 50 mM NH4HCO3, 0.1% N-octyl β-D-
glucopyranoside , 5 mM CaCl2) was added to the dry gel slice and allowed to 
absorb then incubated overnight at 37 °C.  Tryptic fragments were then eluted 3 
times (elution 1 : 10% acetic acid, elution 2 : 30% acetonitrile/5% TFA, elution 3 : 
50% acetonitrile/5% TFA) and the supernatant was dried in a speed vac.  
Extracted protein was then resuspended in water and analyzed by MALDI-TOF 
(Applied Biosystems DE-STR MALDI-TOF mass spectrometer) and ESMS/MS 
(Applied Biosystems QSTAR XL tandem mass spectrometer).  CNBr fragments 
were identified as the smallest digestion product that contained all the tryptic 
fragments found in a given band. 
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RP-HPLC of CNBr digest 
 CNBr digested wild type σ-A was resolved on a Vydac C4 analytical 
column using a 30-55% gradient of buffer B (0.1% (v/v) TFA, 90% (v/v) 
acetonitrile) in buffer A (0.1% (v/v) aqueous TFA).  HPLC was carried out using a 
Hewlett-Packard 1100 series instrument with 214 nm and 280 nm detection.  
Peak fractions were collected and analyzed by ESMS.  CNBr fragments were 
identified by comparing experimentally obtained masses to the masses of 
predicted CNBr digestion products. 
  
Avidin enrichment 
Crosslinked, CNBr digested samples were neutralized with 1N NaOH and 
reduced by treatment with DTT (50 mM).  Samples were boiled and then diluted 
25-fold in 50 mM Tris, 4 mM DTT (pH 8.0) and applied to monomeric avidin resin 
(Promega).  Samples were incubated with gentle rocking for 1 hour at 4 °C then 
washed 3 times with 50 mM Tris, 4 mM DTT (pH 8.0).  Elution was attempted first 
with 50 mM Tris, 0.1% SDS, 4 mM DTT, 5 mM biotin and, after that failed, by 
boiling in SDS loading buffer. 
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Appendix 1 : Additional Fly luciferase traces 
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